

文 献

文献のタイプ

CT: 対照比較試験 GL: ガイドライン・コンセンサス MA: メタ解析 OS: 観察研究 RT: ランダム化比較試験 RV: レビュー

- 1) 循環器病予防研究会. 完全収録第5次循環器疾患基礎調査結果. 中央法規, 2003.
- 2) Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. *J Atheroscler Thromb* 2007; **14**: 278–86. RV
- 3) Kubo M, Kiyohara Y, Kato I, *et al.* Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. *Stroke* 2003; **34**: 2349–54. OS
- 4) Kitamura A, Iso H, Iida M, *et al.* Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. *Am J Med* 2002; **112**: 104–9. OS
- 5) Kimura Y, Takishita S, Muratani H, *et al.* Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. *Intern Med* 1998; **37**: 736–45. OS
- 6) Lawes CM, Rodgers A, Bennett DA, *et al.*; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; **21**: 707–16. MA
- 7) Nippon Data 80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese–Nippon data 80. *J Hum Hypertens* 2003; **17**: 851–7. OS
- 8) Tanizaki Y, Kiyohara Y, Kato I, *et al.* Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. *Stroke* 2000; **31**: 2616–22. OS
- 9) Arima H, Tanizaki Y, Kiyohara Y, *et al.* Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. *Arch Intern Med* 2003; **163**: 361–6. OS
- 10) 健康日本21企画検討会, 健康日本21計画策定検討会. 健康日本21: 21世紀における国民健康づくり運動について: 健康日本21企画検討会・健康日本21計画策定検討会報告書. 健康・体力づくり事業財団, 2000, 177p.
- 11) Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903–13. MA
- 12) Weiner DE, Tighiouart H, Amin MG, *et al.* Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 2004; **15**: 1307–15. MA
- 13) Jafar TH, Stark PC, Schmid CH, *et al.*; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med* 2003; **139**: 244–52. MA
- 14) Iino Y, Hayashi M, Kawamura T, *et al.*; Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. *Hypertens Res* 2004; **27**: 21–30. RT
- 15) Ninomiya T, Kiyohara Y, Kubo M, *et al.* Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. *Kidney Int* 2005; **68**: 228–36. OS
- 16) Nakamura K, Okamura T, Hayakawa T, *et al.*; The NIPPON DATA90 Research Group. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. *Circ J* 2006; **70**: 954–9. OS
- 17) Tanihara S, Hayakawa T, Oki I, *et al.*; NIPPON DATA Research Group. Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980–1999. *J Epidemiol* 2005; **15**: 146–53. OS
- 18) Takeuchi H, Saitoh S, Takagi S, *et al.* Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. *Hypertens Res* 2005; **28**: 203–8. OS
- 19) Iso H, Sato S, Kitamura A, *et al.* Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. *Stroke* 2007; **38**: 1744–51. OS
- 20) Ninomiya T, Kiyohara Y, Kubo M, *et al.* Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. *Am J Kidney Dis* 2006; **48**: 383–91. OS

- 21) Ninomiya T, Kubo M, Doi Y, *et al.* Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. *Stroke* 2007; **38**: 2063–9. OS
- 22) Nakamura Y, Yamamoto T, Okamura T, *et al.*; The NIPPON DATA 80 Research Group. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980–1994. *Circ J* 2006; **70**: 960–4. OS
- 23) Kadota A, Hozawa A, Okamura T, *et al.*; NIPPON DATA Research Group. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990–2000. *Diabetes Care* 2007; **30**: 1533–8. OS
- 24) 斎藤功, 小西正光, 渡辺和子, 近藤広一, 藤本弘一郎, 岡田克俊. 地域集団におけるメタボリックシンドロームの脳卒中罹患に及ぼす影響について. *日本公衛誌* 2007; **54**: 677–83.
- 25) Okayama A, Kadowaki T, Okamura T, Hayakawa T, Ueshima H; The NIPPON DATA80 Research Group. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). *J Hypertens* 2006; **24**: 459–62. OS
- 26) Murakami Y, Hozawa A, Okamura T, Ueshima H; Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Research Group (EPOCH-JAPAN). Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. *Hypertension* 2008; **51**: 1483–91. MA
- 27) Lawes CM, Bennett DA, Parag V, *et al.*; Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. *Hypertension* 2003; **42**: 69–75. OS
- 28) Miura K, Soyama Y, Morikawa Y, *et al.* Comparison of four blood pressure indexes for the prediction of 10-year stroke risk in middle-aged and older Asians. *Hypertension* 2004; **44**: 715–20. OS
- 29) Inoue R, Ohkubo T, Kikuya M, *et al.* Predicting stroke using 4 ambulatory blood pressure monitoring-derived blood pressure indices: the Ohasama Study. *Hypertension* 2006; **48**: 877–82. RT
- 30) Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. *Stroke* 1995; **26**: 361–7. OS
- 31) 磯村孝二. “地域ベースの長期フォローシステムの研究”. 平成5年度厚生省循環器病研究委託費による研究報告集3 指一1, 国立循環器病センター, 1994, p19–28.
- 32) Kita Y, Okayama A, Ueshima H, *et al.* Stroke incidence and case fatality in Shiga, Japan 1989–1993. *Int J Epidemiol* 1999; **28**: 1059–65.
- 33) Kinjo K, Kimura Y, Shinzato Y, *et al.*; COSMO Group. An epidemiological analysis of cardiovascular diseases in Okinawa, Japan. *Hypertens Res* 1992; **15**: 111–119. OS
- 34) Morikawa Y, Nakagawa H, Naruse Y, *et al.* Trends in stroke incidence and acute case fatality in a Japanese rural area: the Oyabe study. *Stroke* 2000; **31**: 1583–7. OS
- 35) Kiyohara Y, Kubo M, Kato I, *et al.* Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. *Stroke* 2003; **34**: 2343–7. OS
- 36) Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. *BMJ* 1988; **297**: 319–28. OS
- 37) Nakagawa H, Morikawa Y, Okayama A, *et al.* Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the Intersalt Study. *J Hum Hypertens* 1999; **13**: 735–41. OS
- 38) Stamler J, Elliott P, Chan Q; INTERMAP Research Group. ITNTERMAP Appendix tables. *J Hum Hypertens* 2003; **17**: 665–775.
- 39) 上島弘嗣. 青壮年者を対象とした生活習慣病予防のための長期介入研究, 平成12年度総括・分担研究報告書, 2001.
- 40) 平成18年国民健康・栄養調査結果の概要. <http://www.mhlw.go.jp/houdou/2008/04/dl/h0430-2a.pdf> (accessed 2008–6–12)
- 41) 児島三郎ほか. “最近10年～20年間にわたる生活環境の変化と循環器疾患の変貌 A. 秋田農村における食生活の変化と循環器疾患. (その1) 昭和20年代後半から昭和30年代後半までの実態”. 循環器疾患の変貌—日本人の栄養と生活環境の関連, 小町喜男ほか編, 東京, 保健同人社, 1987, pp120–138. RV
- 42) The INTERSALT Co-operative Research Group. Appendix tables. Centre-specific results by age and sex. *J Hum Hypertens* 1989; **3**: 331–407.
- 43) Sacks FM, Svetkey LP, Vollmer WM, *et al.*; DASH–Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH–Sodium Collaborative Research Group. *N Engl J Med* 2001; **344**: 3–10. RT
- 44) Nakamura K, Okamura T, Hayakawa T, *et al.*

- NIPPON DATA80, 90 Research Group. The proportion of individuals with obesity-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA80, 90. *Eur J Epidemiol* 2007; **22**: 691–8. OS
- 45) 厚生省公衆衛生局. 昭和55年循環器疾患基礎調査報告. 日本心臓財団, 1982.
- 46) 厚生省公衆衛生局. 第4次循環器疾患基礎調査 (平成2年) 報告. 循環器病振興財団および日本循環器病研究管理協議会, 1993.
- 47) Tanaka T, Okamura T, Yamagata Z, *et al*; HIPOP–OHP Research Group. Awareness and treatment of hypertension and hypercholesterolemia in Japanese workers: the High–risk and Population Strategy for Occupational Health Promotion (HIPOP–OHP) study. *Hypertens Res* 2007; **30**: 921–8. OS
- 48) Hozawa A, Ohkubo T, Kikuya M, *et al*. Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. *Hypertens Res* 2002; **25**: 57–63. OS
- 49) 大久保孝義, 小原拓, 舟橋仁, 菊谷昌浩, 橋本潤一郎, 今井潤. 家庭血圧コントロール状況に関する全国調査研究 (J–HOME 研究) 中間報告: 2003年4月末における対象患者1533人の家庭血圧状況. *Ther Res* 2003; **24**: 1849–55.
- 50) Chobanian AV, Bakris GL, Black HR, *et al*; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; **42**: 1206–52. GL
- 51) Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings. Public health and medical care implications. *Hypertension* 1989; **14**: 570–7. OS
- 52) 常松典子, 上島弘嗣, 奥田奈賀子, 斎藤重幸, 岡山明, 坂田清美, 他, INTERMAP 日本研究班. 減塩食実施者は通常の食生活の人に比べ食塩摂取量がどの程度少ないか? 日循予防誌 2004; **39**: 149–55.
- 53) Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. *Hypertension* 1997; **29**: 22–9. OS
- 54) Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. *J Hum Hypertens* 2005; **19**: 801–7. OS
- 55) Pickering TG, Hall JE, Appel LJ, *et al*; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension* 2005; **45**: 142–61. GL
- 56) O'Brien E, Asmar R, Beilin L, *et al*; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens* 2003; **21**: 821–48. GL
- 57) Ménard J, Chatellier G, Day M, Vaur L. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. *J Hypertens Suppl* 1994; **12**: S21–5. RT
- 58) Oikawa T, Obara T, Ohkubo T, *et al*; J–HOME Study Group. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements: the J–HOME study. *J Hypertens* 2006; **24**: 1737–43. OS
- 59) Funahashi J, Ohkubo T, Fukunaga H, *et al*. The economic impact of the introduction of home blood pressure measurement for the diagnosis and treatment of hypertension. *Blood Press Monit* 2006; **11**: 257–67. OS
- 60) Fukunaga H, Ohkubo T, Kobayashi M, *et al*. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. *J Hypertens* 2008; **26**: 685–690. OS
- 61) 福永英史, 大久保孝義, 小原拓, 菊谷昌浩, 浅山敬, 目時弘仁, 他. わが国における家庭血圧測定の現状: 医師1928人の実践と意義: 家庭血圧測定の現状に関する調査研究. 血圧 2006; **13**: 122–8. OS
- 62) 小原拓, 大久保孝義, 菊谷昌浩, 他. わが国における家庭血圧測定の現状: 外来患者8506人の実践と意義: 家庭血圧測定の現状に関する調査研究. 血圧 2006; **13**: 103–10. OS
- 63) Imai Y, Otsuka K, Kawano Y, *et al*; Japanese Society of Hypertension. Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. *Hypertens Res* 2003; **26**: 771–82. GL
- 64) Imai Y, Obara T, Ohkubo T. How many times should we ask subjects to measure blood pressure at home on each occasion? *J Hypertens* 2007; **25**: 1987–91. GL
- 65) Kawabe H, Saito I. Which measurement of home blood pressure should be used for clinical evaluation

- when multiple measurements are made? *J Hypertens* 2007; **25**: 1369–74. OS
- 66) Ohkubo T, Asayama K, Kikuya M, *et al*; Ohasama Study. How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. *J Hypertens* 2004; **22**: 1099–104. OS
- 67) Imai Y, Munakata M, Tsuji I, *et al*. Seasonal variation in blood pressure in normotensive women studied by home measurements. *Clin Sci (Lond)* 1996; **90**: 55–60. OS
- 68) Kikuya M, Chonan K, Imai Y, Goto E, Ishii M; Research Group to Assess the Validity of Automated Blood Pressure Measurement Devices in Japan. Accuracy and reliability of wrist-cuff devices for self-measurement of blood pressure. *J Hypertens* 2002; **20**: 629–38. OS
- 69) 石光俊彦, 松岡博昭, 南順一, 河野雄平. 高血圧診療における家庭用自動血圧計の有用性に関する検討. *Ther Res* 1997; **18**: 488–93. OS
- 70) 石井當男, 後藤英司. 家庭血圧計の精度管理. *Ther Res* 1998; **19**: 56–59. OS
- 71) Ohkubo T, Imai Y, Tsuji I, *et al*. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. *J Hypertens* 1998; **16**: 971–5. OS
- 72) Sega R, Facchetti R, Bombelli M, *et al*. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. *Circulation* 2005; **111**: 1777–83. OS
- 73) Hozawa A, Ohkubo T, Nagai K, *et al*. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. *Arch Intern Med* 2000; **160**: 3301–6. OS
- 74) Asayama K, Ohkubo T, Kikuya M, *et al*. Use of 2003 European Society of Hypertension – European Society of Cardiology guidelines for predicting stroke using self-measured blood pressure at home: the Ohasama study. *Eur Heart J* 2005; **26**: 2026–31. OS
- 75) Asayama K, Ohkubo T, Kikuya M, *et al*. Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 classification: the Ohasama study. *Stroke* 2004; **35**: 2356–61. OS
- 76) Nishinaga M, Takata J, Okumiya K, Matsubayashi K, Ozawa T, Doi Y. High morning home blood pressure is associated with a loss of functional independence in the community-dwelling elderly aged 75 years or older. *Hypertens Res* 2005; **28**: 657–63. OS
- 77) Stergiou GS, Baibas NM, Kalogeropoulos PG. Cardiovascular risk prediction based on home blood pressure measurement: the Didima study. *J Hypertens* 2007; **25**: 1590–6. OS
- 78) Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. *Kidney Int* 2006; **69**: 406–11. OS
- 79) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997; **157**: 2413–46. GL
- 80) European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003; **21**: 1011–53. GL
- 81) Guidelines Subcommittee. 1999 World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension. *J Hypertens* 1999; **17**: 151–83. GL
- 82) Tsuji I, Imai Y, Nagai K, *et al*. Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. *Am J Hypertens* 1997; **10**: 409–18. OS
- 83) Imai Y, Ohkubo T, Tsuji I, *et al*. Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. *Blood Press Monit* 1996; **1** (Suppl 2): S51–S58. OS
- 84) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン2004. 東京, 日本高血圧学会, 2004. GL
- 85) Mancia G, De Backer G, Dominiczak A, *et al*; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Management of Arterial Hypertension of the European Society of Hypertension. 2007 Guidelines for the Management of Arterial Hypertension. *J Hypertens* 2007; **25**: 1105–87. GL
- 86) Fujiwara T, Nishimura T, Ohkubo T, Imai Y; HOMED-BP Study Group. Rationale and design of HOMED-BP Study: hypertension objective treatment

- based on measurement by electrical devices of blood pressure study. *Blood Press Monit* 2002; 7: 77–82. RT
- 87) Imai Y, Abe K, Sasaki S, *et al.* Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. *Am J Hypertens* 1990; 3: 293–301. OS
 - 88) Imai Y, Sasaki S, Minami N, *et al.* The accuracy and performance of the A & D TM 2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric method and the Korotkoff sound technique. *Am J Hypertens* 1992; 5: 719–26. OS
 - 89) Kuwajima I, Nishinaga M, Kanamaru A. The accuracy and clinical performance of a new compact ambulatory blood pressure monitoring device, the ES-H531. *Am J Hypertens* 1998; 11: 1328–33. OS
 - 90) 島田和幸, 今井潤, 桑島巖, 他. 24時間血圧計の使用 (ABPM) 基準に関するガイドライン. *Jpn Circ J* 2000; 64: 1207–48. GL
 - 91) Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. *Circulation* 1966; 34: 279–98. OS
 - 92) Mancia G, Zanchetti A, Agabiti-Rosei E, *et al.*; SAMPLE Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. *Circulation* 1997; 95: 1464–70. OS
 - 93) Ohkubo T, Hozawa A, Nagai K, *et al.* Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. *J Hypertens* 2000; 18: 847–54. OS
 - 94) Suzuki Y, Kuwajima I, Aono T, *et al.* Prognostic value of nighttime blood pressure in the elderly: a prospective study of 24-hour blood pressure. *Hypertens Res* 2000; 23: 323–30. OS
 - 95) Staessen JA, Thijs L, Fagard R, *et al.*; Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA* 1999; 282: 539–46. OS
 - 96) Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. *Am J Nephrol* 2006; 26: 503–10. OS
 - 97) Kikuya M, Ohkubo T, Asayama K, *et al.* Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. *Hypertension* 2005; 45: 240–5. OS
 - 98) Verdecchia P, Porcellati C, Schillaci G, *et al.* Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. *Hypertension* 1994; 24: 793–801. OS
 - 99) 川崎晃一, 上園慶子. “臨床的に健常な日本人の血圧日内変動の基準値設定の試み”. 血圧モニタリングの臨床, 尾前照雄監, 川崎晃一編, 東京, 医学書院, 1993, pp181–189. GL
 - 100) Kikuya M, Hansen TW, Thijs L, *et al.*; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. *Circulation* 2007; 115: 2145–52. OS
 - 101) Kikuya M, Hozawa A, Ohkubo T, *et al.* Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension* 2000; 36: 901–6. OS
 - 102) Ugajin T, Hozawa A, Ohkubo T, *et al.* White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. *Arch Intern Med* 2005; 165: 1541–6. OS
 - 103) Verdecchia P, Reboldi GP, Angeli F, *et al.* Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension* 2005; 45: 203–8. OS
 - 104) Ohkubo T, Imai Y, Tsuji I, *et al.* Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. *Am J Hypertens* 1997; 10: 1201–7. OS
 - 105) Kario K, Pickering TG, Umeda Y, *et al.* Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation* 2003; 107: 1401–6. OS
 - 106) Chonan K, Hashimoto J, Ohkubo T, *et al.* Insufficient duration of action of antihypertensive drugs mediates high blood pressure in the morning in hypertensive population: the Ohasama study. *Clin Exp Hypertens* 2002; 24: 261–75. OS
 - 107) Bobrie G, Chatellier G, Genes N, *et al.* Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA* 2004; 291: 1342–9. OS
 - 108) Ohkubo T, Kikuya M, Metoki H, *et al.* Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. *J Am Coll Cardiol* 2005; 46: 508–15. OS
 - 109) Harada K, Karube Y, Saruhara H, Takeda K, Kuwajima I. Workplace hypertension is associated

- with obesity and family history of hypertension. *Hypertens Res* 2006; **29**: 969–76. OS
- 110) Metoki H, Ohkubo T, Kikuya M, *et al*. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. *Hypertension* 2006; **47**: 149–54. OS
 - 111) Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O. Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. *Diabetes Care* 2002; **25**: 2218–23. OS
 - 112) Asayama K, Ohkubo T, Kikuya M, *et al*. Prediction of stroke by home “morning” versus “evening” blood pressure values: the Ohasama study. *Hypertension* 2006; **48**: 737–43. OS
 - 113) Kario K, Ishikawa J, Pickering TG, *et al*. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. *Hypertens Res* 2006; **29**: 581–7. OS
 - 114) Chonan K, Kikuya M, Araki T, *et al*. Device for the self-measurement of blood pressure that can monitor blood pressure during sleep. *Blood Press Monit* 2001; **6**: 203–5. OS
 - 115) Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. *Hypertension* 1990; **16**: 692–9. OS
 - 116) Verdecchia P, Schillaci G, Guerrieri M, *et al*. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. *Circulation* 1990; **81**: 528–36. OS
 - 117) Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. *Am J Hypertens* 1994; **7**: 23–9. OS
 - 118) Ohkubo T, Hozawa A, Yamaguchi J, *et al*. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. *J Hypertens* 2002; **20**: 2183–9. OS
 - 119) Shimada K, Imai Y, Kuwajima I, Abe K. Patients characteristics and effects of the long-term acting calcium channel blocker barnidipine on circadian blood pressure changes: results of the Japanese Multicenter Study on Barnidipine with Ambulatory Blood Pressure Monitoring. *Blood Press Monit* 2001; **6**: S25–S30. OS
 - 120) Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. *Hypertension* 1996; **27**: 130–5. OS
 - 121) Boggia J, Li Y, Thijs L, *et al*; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. *Lancet* 2007; **370**: 1219–29. MA
 - 122) Kelly R, Fitchett D. Noninvasive determination of aortic input impedance and external left ventricular power output: a validation and repeatability study of a new technique. *J Am Coll Cardiol* 1992; **20**: 952–63. OS
 - 123) Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. *Hypertension* 2001; **38**: 932–7. OS
 - 124) Pauca AL, Kon ND, O'Rourke MF. The second peak of the radial artery pressure wave represents aortic systolic pressure in hypertensive and elderly patients. *Br J Anaesth* 2004; **92**: 651–7. OS
 - 125) Hashimoto J, Watabe D, Hatanaka R, *et al*. Enhanced radial late systolic pressure augmentation in hypertensive patients with left ventricular hypertrophy. *Am J Hypertens* 2006; **19**: 27–32. OS
 - 126) Williams B, Lacy PS, Thom SM, *et al*; CAFE Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006; **113**: 1213–25. RT
 - 127) Agabiti-Rosei E, Mancia G, O'Rourke MF, *et al*. Central blood pressure measurements and antihypertensive therapy: a consensus document. *Hypertension* 2007; **50**: 154–60. GL
 - 128) Hashimoto J, Imai Y, O'Rourke MF. Monitoring of antihypertensive therapy for reduction in left ventricular mass. *Am J Hypertens* 2007; **20**: 1229–33. CT
 - 129) Ueda K, Omae T, Hasuo Y, *et al*. Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. *J Hypertens* 1988; **6**: 991–7. OS
 - 130) Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. *Circulation* 1999; **100**: 354–60. OS
 - 131) Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. *Am Heart J* 1987; **113**: 1489–94. OS
 - 132) Palatini P, Benetos A, Grassi G, *et al*; European

- Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. *J Hypertens* 2006; **24**: 603–10. GL
- 133) Palatini P, Thijs L, Staessen JA, *et al*; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. *Arch Intern Med* 2002; **162**: 2313–21. OS
 - 134) Hozawa A, Ohkubo T, Kikuya M, *et al*. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. *Am J Hypertens* 2004; **17**: 1005–10. OS
 - 135) Benetos A, Zureik M, Morcet J, *et al*. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. *J Am Coll Cardiol* 2000; **35**: 673–80. OS
 - 136) Staessen JA, Gasowski J, Wang JG, *et al*. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet* 2000; **355**: 865–72. MA
 - 137) Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. *Hypertension* 1989; **13**: 392–400. OS
 - 138) Benetos A, Safar M, Rudnicki A, *et al*. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. *Hypertension* 1997; **30**: 1410–5. OS
 - 139) Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens* 2003; **21**: 1983–92. GL
 - 140) 島本和明. 高血圧管理・治療の新しい動向 (JNC-VIとわが国の現状). 日内会誌 1999; **88**: 401–5. RV
 - 141) MacMahon S, Peto R, Cutler J, *et al*. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; **335**: 765–74. MA
 - 142) Vasan RS, Larson MG, Leip EP, *et al*. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med* 2001; **345**: 1291–7. OS
 - 143) Shimamoto K, Kita T, Mabuchi H, *et al*; J-LIT Study Group. The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study. *Hypertens Res* 2005; **28**: 879–87. OS
 - 144) Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. *Lancet* 2001; **358**: 1682–6. OS
 - 145) Kassai B, Gueyffier F, Boissel JP, Boutitie F, Cucherat M. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? *J Clin Epidemiol* 2003; **56**: 977–82.
 - 146) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日内会誌 2005; **94**: 794–809. GL
 - 147) National Kidney Foundation. Executive summary. *Am J Kidney Dis* 2004; **43**: s16–33. GL
 - 148) Arnlöv J, Evans JC, Meigs JB, *et al*. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 2005; **112**: 969–75. OS
 - 149) Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. *J Hypertens* 2004; **22**: 1635–9. RV
 - 150) Rahman M, Pressel S, Davis BR, *et al*; ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. *Ann Intern Med* 2006; **144**: 172–80. OS
 - 151) Nakayama M, Metoki H, Terawaki H, *et al*. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. *Nephrol Dial Transplant* 2007; **22**: 1910–5. OS
 - 152) Irie F, Iso H, Sairenchi T, *et al*. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. *Kidney Int* 2006; **69**: 1264–71. OS
 - 153) de Leeuw PW, Ruilope LM, Palmer CR, *et al*. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. *Arch Intern Med* 2004; **164**: 2459–64. RT
 - 154) Turnbull F, Neal B, Algert C, *et al*; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and

- without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med* 2005; **165**: 1410–9. MA
- 155) PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; **358**: 1033–41. RT
 - 156) UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; **317**: 703–13. RT
 - 157) Fujishima M, Kiyohara Y, Kato I, *et al.* Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. *Diabetes* 1996; **45**: S14–6. OS
 - 158) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況 (2006年12月31日現在). 日透析医学会誌 2008; **41**: 1–28.
 - 159) Hansson L, Zanchetti A, Carruthers SG, *et al*; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998; **351**: 1755–62. RT
 - 160) Brenner BM, Cooper ME, de Zeeuw D, *et al*; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; **345**: 861–9. RT
 - 161) Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 2002; **61**: 1086–97. RT
 - 162) Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. *Kidney Int Suppl* 1996; **55**: S57–62. CT
 - 163) Asayama K, Ohkubo T, Satoh A, *et al.* Proposal of a risk-stratification system for the Japanese population based on blood pressure levels: the Ohasama Study. *Hypertens Res* 2008; **31**: 1315–22. OS
 - 164) Rydén L, Standl E, Bartnik M, *et al*; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007; **28**: 88–136. GL
 - 165) Hashimoto H, Kitagawa K, Hougaku H, *et al.* C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. *Circulation* 2001; **104**: 63–7. CT
 - 166) Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. *Hypertens Res* 2007; **30**: 1177–85. CT
 - 167) Ishikawa J, Tamura Y, Hoshida S, *et al.* Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. *Stroke* 2007; **38**: 911–7. RT
 - 168) Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. *Stroke* 1997; **28**: 1932–9.
 - 169) Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshida S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Am Coll Cardiol* 2001; **38**: 238–45. OS
 - 170) Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM; Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. *Stroke* 2003; **34**: 1126–9. OS
 - 171) Naka H, Nomura E, Takahashi T, *et al.* Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. *AJNR Am J Neuroradiol* 2006; **27**: 830–5. OS
 - 172) Gauthier S, Reisberg B, Zaudig M, *et al*; International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. *Lancet* 2006; **367**: 1262–70. RV
 - 173) Cooper LS, Wong TY, Klein R, *et al.* Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: the Atherosclerosis Risk in Communities Study. *Stroke* 2006; **37**: 82–6. OS
 - 174) Salles G, Cardoso C, Nogueira AR, Bloch K, Muxfeldt E. Importance of the electrocardiographic strain pattern in patients with resistant hypertension. *Hypertension* 2006; **48**: 437–42.
 - 175) Okin PM, Devereux RB, Jern S, *et al*; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. *JAMA* 2004; **292**: 2343–9. OS

- 176) Watanabe H, Tanabe N, Watanabe T, *et al.* Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. *Circulation* 2008; **117**: 1255–60. OS
- 177) Muiesan ML, Salvetti M, Monteduro C, *et al.* Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. *Hypertension* 2004; **43**: 731–8. OS
- 178) Eguchi K, Kario K, Hoshida S, Ishikawa J, Morinari M, Shimada K. Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients. *Am J Hypertens* 2005; **18**: 23–9. OS
- 179) Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. *Nature* 1988; **332**: 78–81. OS
- 180) Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. *Kidney Int* 2003; **63**: 1468–74.
- 181) Sarnak MJ, Levey AS, Schoolwerth AC, *et al*; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003; **108**: 2154–69. GL
- 182) Matsuo S, Imai E, Horio M, *et al*; the collaborators for developing Japanese equation for estimating GFR. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. *Am J Kidney Dis* (in press). OS
- 183) Gerber LM, Schwartz JE, Pickering TG. Albumin-to-creatinine ratio predicts change in ambulatory blood pressure in normotensive persons: a 7.5-year prospective study. *Am J Hypertens* 2006; **19**: 220–6. OS
- 184) Ibsen H, Olsen MH, Wachtell K, *et al.* Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. *Hypertension* 2005; **45**: 198–202. OS
- 185) 日本脳神経超音波学会・栓子検出と治療学会合同ガイドライン作成委員会. 頸部血管超音波検査ガイドライン/頭蓋内超音波検査ガイドライン/塞栓源検索 (心臓と下肢静脈) ガイドライン. *Neurosonology* 2006; **19**: 49–69. GL
- 186) Nagai Y, Matsumoto M, Metter EJ. The carotid artery as a noninvasive window for cardiovascular risk in apparently healthy individuals. *Ultrasound Med Biol* 2002; **28**: 1231–8. RV
- 187) Takiuchi S, Rakugi H, Honda K, *et al.* Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. *Circulation* 2000; **102**: 766–70.
- 188) Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW; Framingham Study. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med* 2003; **163**: 1939–42. OS
- 189) Yamashina A, Tomiyama H, Takeda K, *et al.* Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res* 2002; **25**: 359–64.
- 190) Tomiyama H, Hashimoto H, Hirayama Y, *et al.* Synergistic acceleration of arterial stiffening in the presence of raised blood pressure and raised plasma glucose. *Hypertension* 2006; **47**: 180–8.
- 191) Munakata M, Nunokawa T, Yoshinaga K, Toyota T; J-TOPP Study Group. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension—a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). *Hypertens Res* 2006; **29**: 515–21. OS
- 192) Yambe M, Tomiyama H, Yamada J, *et al.* Arterial stiffness and progression to hypertension in Japanese male subjects with high normal blood pressure. *J Hypertens* 2007; **25**: 87–93. OS
- 193) Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. *Hypertens Res* 2007; **30**: 219–28. CT
- 194) Rose KM, Eigenbrodt ML, Biga RL, *et al.* Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. *Circulation* 2006; **114**: 630–6. OS
- 195) Kario K, Eguchi K, Hoshida S, *et al.* U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. *J Am Coll Cardiol* 2002; **40**: 133–41. OS
- 196) Kario K, Shimada K, Pickering TG. Abnormal nocturnal blood pressure falls in elderly hypertension: clinical significance and determinants. *J Cardiovasc Pharmacol* 2003; **41 Suppl 1**: S61–6. OS
- 197) Kohara K, Tabara Y, Yamamoto Y, Miki T. Orthostatic hypertension: another orthostatic disorder to be

- aware of. *J Am Geriatr Soc* 2000; **48**: 1538–9.
- 198) Lever AF, Ramsay LE. Treatment of hypertension in the elderly. *J Hypertens* 1995; **13**: 571–9. OS
 - 199) Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. *J Am Coll Cardiol* 1996; **27**: 1214–8. MA
 - 200) Psaty BM, Smith NL, Siscovick DS, *et al*. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA* 1997; **277**: 739–45. MA
 - 201) Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Textbook of Hypertension. Swales JD, editor. London: Blackwell Scientific Publication; 1994, p. 1156–1164.
 - 202) Whelton PK, He J. Blood pressure reduction. In: Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Hennekens CH, editor. Philadelphia: W. B. Saunders Co.; 1999, p. 341–359.
 - 203) Gueyffier F, Boutitie F, Boissel JP, *et al*. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. *Ann Intern Med* 1997; **126**: 761–7. MA
 - 204) MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. *Clin Exp Hypertens* 1993; **15**: 967–78. MA
 - 205) Beckett NS, Peters R, Fletcher AE, *et al*; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008; **358**: 1887–98. RT
 - 206) Takagi S, Saitoh S, Nakano M, *et al*. Relationship between blood pressure level and mortality rate: an 18-year study conducted in two rural communities in Japan. *J Hypertens* 2000; **18**: 139–44. OS
 - 207) Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens* 2005; **23**: 2157–72. RT
 - 208) Arima H, Chalmers J, Woodward M, *et al*; PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. *J Hypertens* 2006; **24**: 1201–8. OS
 - 209) Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003; **362**: 782–8. RT
 - 210) Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. *J Hypertens* 2005; **23**: 641–8. CT
 - 211) Nissen SE, Tuzcu EM, Libby P, *et al*; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA* 2004; **292**: 2217–25. RT
 - 212) Appel LJ, Moore TJ, Obarzanek E, *et al*. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med* 1997; **336**: 1117–24. RT
 - 213) Whelton PK, Appel LJ, Espeland MA, *et al*; TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). *JAMA* 1998; **279**: 839–46. RT
 - 214) Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G. Walking to work and the risk for hypertension in men: the Osaka Health Survey. *Ann Intern Med* 1999; **131**: 21–6. OS
 - 215) Neaton JD, Grimm RH, Prineas RJ, *et al*; Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. *JAMA* 1993; **270**: 713–24. RT
 - 216) Singer DR, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. *Hypertension* 1995; **25**: 1042–4. RT
 - 217) Mochizuki S, Dahlöf B, Shimizu M, *et al*; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. *Lancet* 2007; **369**: 1431–9. RT
 - 218) Ogihara T, Nakao K, Fukui T, *et al*; Candesartan Antihypertensive Survival Evaluation in Japan Trial

- Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. *Hypertension* 2008; **51**: 393–8. RT
- 219) Dahlöf B, Devereux RB, Kjeldsen SE, *et al*; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; **359**: 995–1003. RT
- 220) Dahlöf B, Sever PS, Poulter NR, *et al*; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. *Lancet* 2005; **366**: 895–906. RT
- 221) Julius S, Kjeldsen SE, Weber M, *et al*; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004; **363**: 2022–31. RT
- 222) Weber MA, Julius S, Kjeldsen SE, *et al*. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. *Lancet* 2004; **363**: 2049–51. CT
- 223) Wing LM, Brown MA, Beilin LJ, Ryan P, Reid CM; ANBP2 Management Committee and Investigators. Second Australian National Blood Pressure Study. ‘Reverse white-coat hypertension’ in older hypertensives. *J Hypertens* 2002; **20**: 639–44. OS
- 224) Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 2007; **369**: 201–7. MA
- 225) Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. *Hypertens Res* 2003; **26**: 159–62. CT
- 226) Yoshida K, Matsuoka H, Omae T, Fujii J. Patient–hospital relationship and quality of life in elderly patients with hypertension. *Hypertens Res* 1995; **18**: 77–83. OS
- 227) Kaplan NM. Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension. *Arch Intern Med* 1997; **157**: 945–8.
- 228) Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzuza-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. *J Hypertens* 2003; **21**: 1283–9. OS
- 229) Dimenäs ES, Wiklund IK, Dahlöf CG, Lindvall KG, Olofsson BK, De Faire UH. Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. *J Hypertens* 1989; **7**: 885–90.
- 230) 三上洋, 荻原俊男. 高齢者の薬物療法とQOL. *日老医誌* 1999; **36**: 186–90.
- 231) Croog SH, Levine S, Testa MA, *et al*. The effects of antihypertensive therapy on the quality of life. *N Engl J Med* 1986; **314**: 1657–64. RT
- 232) Grimm RH, Grandits GA, Cutler JA, *et al*. Relationships of quality-of-life measures to long-term life-style and drug treatment in the Treatment of Mild Hypertension Study. *Arch Intern Med* 1997; **157**: 638–48. RT
- 233) Degl’Innocenti A, Elmfeldt D, Hofman A, *et al*. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). *J Hum Hypertens* 2004; **18**: 239–45. RT
- 234) Bane C, Hughes CM, Cupples ME, McElnay JC. The journey to concordance for patients with hypertension: a qualitative study in primary care. *Pharm World Sci* 2007; **29**: 534–40.
- 235) 齊藤郁夫. 未治療および治療中患者と医師の高血圧治療、高血圧合併症の認識の乖離. *Prog Med* 2008; **28**: 1215–22.
- 236) Roumie CL, Elasy TA, Greevy R, *et al*. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. *Ann Intern Med* 2006; **145**: 165–75. RT
- 237) Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. *JAMA* 2006; **296**: 2563–71. RT
- 238) 齊藤郁夫. 服薬コンプライアンスと血圧コントロール; 降圧薬の薬剤数が服薬コンプライアンスに及ぼす影響. *血圧* 2006; **13**: 1019–25.
- 239) Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. *Arch Intern Med* 2004; **164**: 722–32. RV
- 240) Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med* 2007; **120**: 713–9. MA

- 241) Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B; LIFE Study Group. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. *J Hypertens* 2005; **23**: 1425–31. OS
- 242) Saito I, Fujikawa K, Saruta T; ADVANCE-Combi study group. Cost-effectiveness analysis: Controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: The adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. *Hypertens Res* 2008; **31**: 1399–405. OS
- 243) Barzilay JL, Davis BR, Cutler JA, *et al*; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med* 2006; **166**: 2191–201. RT
- 244) 齊藤郁夫, 小林慎, 猿田享男. 本態性高血圧患者に対する降圧薬治療の薬剤経済性分析. *臨床医薬* 2003; **19**: 777–88.
- 245) Heidenreich PA, Davis BR, Cutler JA, *et al*. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Gen Intern Med* 2008; **23**: 509–16. RT
- 246) Saito I, Kobayashi M, Matsushita Y, Saruta T. Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. *Jpn Med Assoc J* 2005; **48**: 574–585.
- 247) Kawano Y, Ando K, Matsuura H, Tsuchihashi T, Fujita T, Ueshima H; Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) Rationale for salt restriction and salt-restriction target level for the management of hypertension. *Hypertens Res* 2007; **30**: 879–86.
- 248) He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *J Hum Hypertens* 2002; **16**: 761–70. MA
- 249) 松浦秀夫, 中東教江. 日本高血圧学会減塩ワーキンググループ報告: 高血圧患者さんのための減塩食レシピ, 日本高血圧学会減塩ワーキンググループ編, 日本高血圧学会, 2006. GL
- 250) Lichtenstein AH, Appel LJ, Brands M, *et al*; American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation* 2006; **114**: 82–96. GL
- 251) Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension* 2006; **47**: 296–308. GL
- 252) Ohta Y, Tsuchihashi T, Ueno M, *et al*. Relationship between the awareness of salt restriction and the actual salt intake in hypertensive patients. *Hypertens Res* 2004; **27**: 243–6.
- 253) Cook NR, Cutler JA, Obarzanek E, *et al*. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ* 2007; **334**: 885. MA
- 254) Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, Ueshima H; Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. *Hypertens Res* 2007; **30**: 887–93.
- 255) Geleijnse JM, Hofman A, Witteman JC, Hazebroek AA, Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium restriction on blood pressure. *Hypertension* 1997; **29**: 913–7. RT
- 256) 第一出版編集部編: 厚生労働省・農林水産省決定: 食事バランスガイド—フードガイド (仮称) 検討委員会報告書, 東京, 第一出版, 2005. GL
- 257) Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G; DASH-Sodium Trial Collaborative Research Group. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure–natriuresis relationship. *Hypertension* 2003; **42**: 8–13. RT
- 258) Azadbakht L, Mirmiran P, Esmailzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. *Diabetes Care* 2005; **28**: 2823–31. RT
- 259) He K, Liu K, Daviglus ML, *et al*. Magnesium intake and incidence of metabolic syndrome among young adults. *Circulation* 2006; **113**: 1675–82. OS
- 260) Ueshima H, Stamler J, Elliott P, *et al*; INTERMAP Research Group. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and

- their blood pressure: INTERMAP study. *Hypertension* 2007; **50**: 313–9. OS
- 261) Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. *J Hypertens* 2002; **20**: 1493–9. MA
- 262) Iso H, Kobayashi M, Ishihara J, *et al*; JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. *Circulation* 2006; **113**: 195–202. OS
- 263) Fox CS, Massaro JM, Hoffmann U, *et al*. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation* 2007; **116**: 39–48. OS
- 264) Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2003; **42**: 878–84. MA
- 265) Dickinson HO, Mason JM, Nicolson DJ, *et al*. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens* 2006; **24**: 215–33. MA
- 266) Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. *N Engl J Med* 1993; **328**: 533–7. OS
- 267) Haskell WL, Lee IM, Pate RR, *et al*; American College of Sports Medicine. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation* 2007; **116**: 1081–93. GL
- 268) Tashiro E, Miura S, Koga M, *et al*. Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. *Clin Exp Pharmacol Physiol* 1993; **20**: 689–96. RT
- 269) Shaper AG, Wannamethee G, Walker M. Physical activity, hypertension and risk of heart attack in men without evidence of ischaemic heart disease. *J Hum Hypertens* 1994; **8**: 3–10.
- 270) 運動所要量・運動指針の策定検討会: 健康づくりのための運動指針2006～生活習慣病予防のために～ [internet], 東京, 厚生労働省, 2006年7月 [参照日: 2008年1月29日], <http://www.mhlw.go.jp/bunya/kenkou/undou01/pdf/data.pdf>.
- 271) Ohkubo T, Hozawa A, Nagatomi R, *et al*. Effects of exercise training on home blood pressure values in older adults: a randomized controlled trial. *J Hypertens* 2001; **19**: 1045–52. RT
- 272) Nakamura K, Okamura T, Hayakawa T, *et al*; NIPPON DATA90 Research Group. The proportion of individuals with alcohol-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA90. *Hypertens Res* 2007; **30**: 663–8. OS
- 273) Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. *Circulation* 2007; **116**: 1306–17. RV
- 274) Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2001; **38**: 1112–7. MA
- 275) Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. *Lancet* 1987; **329**: 647–51. RT
- 276) Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. *J Hypertens* 1992; **10**: 495–9.
- 277) Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. *Hypertension* 1999; **33**: 586–90. RT
- 278) Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. *Hypertens Res* 2007; **30**: 479–88. RV
- 279) Halperin RO, Gaziano JM, Sesso HD. Smoking and the risk of incident hypertension in middle-aged and older men. *Am J Hypertens* 2008; **21**: 148–52. OS
- 280) Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in 't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. *Ann Intern Med* 1998; **129**: 705–11.
- 281) Miyatake N, Wada J, Kawasaki Y, Nishii K, Makino H, Numata T. Relationship between metabolic syndrome and cigarette smoking in the Japanese population. *Intern Med* 2006; **45**: 1039–43. OS
- 282) 松岡博昭, 瀧下修一. 禁煙宣言 [internet], 東京, 日本高血圧学会, 2007年10月26日 [参照日: 2008年1月29日] <http://www.jpnh.org/news/tabaccocontrol.pdf>.
- 283) The Eurowinter Group. Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe. *Lancet* 1997; **349**: 1341–6. OS
- 284) Espeland MA, Whelton PK, Kostis JB, *et al*; TONE Cooperative Research Group. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. *Arch Fam Med* 1999; **8**: 228–

36. RT
- 285) Appel LJ, Champagne CM, Harsha DW, *et al*; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA*; 289: 2083–93. RT
- 286) Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 2003; 362: 1527–35. MA
- 287) Turnbull F, Neal B, Pfeffer M, *et al*; Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *J Hypertens* 2007; 25: 951–8. MA
- 288) British Hypertension Society guidelines (BHS-IV). *J Fam Pract* 2004; 53: 528–50. GL
- 289) Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. *Am J Hypertens* 2001; 14: 241–7. RV
- 290) Hansson L, Lindholm LH, Ekbom T, *et al*. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999; 354: 1751–6. RT
- 291) Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. *J Hypertens Suppl* 1999; 17: S21–5. RV
- 292) Karlberg BE, Lins LE, Hermansson K; TEES Study Group. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. *J Hypertens* 1999; 17: 293–302. RT
- 293) Ohkubo T, Obara T, Funahashi J, *et al*; J-HOME Study Group. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. *Hypertens Res* 2004; 27: 755–63. OS
- 294) Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents—a preliminary report. *Hypertension* 2007; 49: 272–5. RT
- 295) Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ* 2003; 326: 1427. MA
- 296) Hermida RC, Ayala DE, Calvo C, *et al*. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. *Hypertension* 2005; 46: 1053–9.
- 297) Elliott WJ. Drug interactions and drugs that affect blood pressure. *J Clin Hypertens (Greenwich)* 2006; 8: 731–7. RV
- 298) Sugiyama T, Kiraku J, Ashida T, Fujii J. Remission of hypertension: retrospective observations over a period of 20 years. *Hypertens Res* 1998; 21: 103–8.
- 299) Terpstra WF, May JF, Smit AJ, *et al*. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. *J Hypertens* 2001; 19: 303–9. RT
- 300) Sipahi I, Tuzcu EM, Schoenhagen P, *et al*. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. *J Am Coll Cardiol* 2006; 48: 833–8. CT
- 301) Fujita T, Ando K, Nishimura H, *et al*; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. *Kidney Int* 2007; 72: 1543–9. RT
- 302) Ishimitsu T, Kameda T, Akashiba A, *et al*. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. *Hypertens Res* 2007; 30: 621–6. RT
- 303) Nakamura T, Sugaya T, Kawagoe Y, *et al*. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. *Am J Med Sci* 2007; 333: 321–6. RT
- 304) Ohishi M, Takagi T, Ito N, *et al*. Renal-protective effect of T- and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. *Hypertens Res* 2007; 30: 797–806. CT
- 305) Zou Y, Akazawa H, Qin Y, *et al*. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. *Nat Cell Biol* 2004; 6: 499–506.
- 306) Yusuf S, Teo KK, Pogue J, *et al*; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008; 358: 1547–59. RT
- 307) Lindholm LH, Ibsen H, Dahlöf B, *et al*; LIFE Study

- Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; **359**: 1004–10. RT
- 308) Arai T, Sekizawa K, Ohru T, *et al*. ACE inhibitors and protection against pneumonia in elderly patients with stroke. *Neurology* 2005; **64**: 573–4. OS
- 309) National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. *Hypertension* 1999; **34**: 1129–33. RT
- 310) Messerli FH, Grossman E, Goldbourt U. β -blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA* 1998; **279**: 1903–7. MA
- 311) Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. *N Engl J Med* 2000; **342**: 905–12. OS
- 312) Bakris GL, Fonseca V, Katholi RE, *et al*; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; **292**: 2227–36. RT
- 313) Karachalios GN, Charalabopoulos A, Papalimneou V, *et al*. Withdrawal syndrome following cessation of antihypertensive drug therapy. *Int J Clin Pract* 2005; **59**: 562–70. RV
- 314) Flack JM, Oparil S, Pratt JH, *et al*. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *J Am Coll Cardiol* 2003; **41**: 1148–55. RT
- 315) Pitt B, Zannad F, Remme WJ, *et al*; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999; **341**: 709–17. RT
- 316) Pitt B, Remme W, Zannad F, *et al*; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; **348**: 1309–21. RT
- 317) Chapman N, Dobson J, Wilson S, *et al*; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension* 2007; **49**: 839–45. RT
- 318) Hasebe N, Kikuchi K; NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. *J Hypertens* 2005; **23**: 445–53. RT
- 319) Saito I, Saruta T; ADVANCE-Combi Study Group. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. *Hypertens Res* 2006; **29**: 789–96. RT
- 320) Pepine CJ, Handberg EM, Cooper-DeHoff RM, *et al*; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA* 2003; **290**: 2805–16. RT
- 321) Poole-Wilson PA, Lubsen J, Kirwan BA, *et al*; A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. *Lancet*; **364**: 849–57. RT
- 322) Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Usefulness of the α_1 -blocker doxazosin as a third-line antihypertensive drug. *Hypertens Res* 2007; **30**: 301–6. CT
- 323) Patel A, MacMahon S, Chalmers J, *et al*; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007; **370**: 829–40. RT
- 324) Jamerson K, Weber MA, Bakris GL, *et al*; ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med* 2008; **359**: 2417–28. RT
- 325) Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. *N Engl J Med* 2006; **355**: 385–92. RV
- 326) Cuspidi C, Macca G, Sampieri L, *et al*. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. *J Hypertens* 2001; **19**: 2063–70. OS
- 327) Kaplan NM. Treatment of hypertension. In: Kaplan's

- clinical hypertension, 9th edition. Philadelphia: Lippincott Williams & Wilkins; 2006, pp217–310.
- 328) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; **288**: 2981–97. RT
 - 329) Black HR, Elliott WJ, Grandits G, *et al*; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA* 2003; **289**: 2073–82. RT
 - 330) Brown MJ, Palmer CR, Castaigne A, *et al*. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 2000; **356**: 366–72. RT
 - 331) Ogihara T, Nakao K, Fukui T, *et al*. The optimal target blood pressure for antihypertensive treatment in the Japanese elderly patients with high-risk hypertension: a subanalysis of Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. *Hypertens Res* 2008; **31**: 1595–601. CT
 - 332) Obara T, Ohkubo T, Funahashi J, *et al*. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. *J Hypertens* 2005; **23**: 1653–60. OS
 - 333) Mori H, Ukai H, Yamamoto H, *et al*. Current status of antihypertensive prescription and associated blood pressure control in Japan. *Hypertens Res* 2006; **29**: 143–51. OS
 - 334) Ohta Y, Tsuchihashi T, Fujii K, *et al*. Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. *J Hum Hypertens* 2004; **18**: 273–8. OS
 - 335) Ono A, Fujita T. Factors relating to inadequate control of blood pressure in hypertensive outpatients. *Hypertens Res* 2003; **26**: 219–24. OS
 - 336) Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. *Am J Hypertens* 2003; **16**: 925–30. CT
 - 337) Calhoun DA, Jones D, Textor S, *et al*. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the american heart association professional education committee of the council for high blood pressure research. *Hypertension* 2008; **51**: 1403–19. GL
 - 338) Broderick JP, Adams HP, Barsan W, *et al*. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1999; **30**: 905–15. GL
 - 339) Adams HP, Brott TG, Crowell RM, *et al*. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1994; **25**: 1901–14. GL
 - 340) 栗山良紘. CBF (cerebral blood flow) autoregulationおよび降圧治療. ACE inhibitors; innovative clinical applications. 猿田享男他監, 東京; Medical Tribune, 1990, p. 89–96.
 - 341) Bath P, Chalmers J, Powers W, *et al*; International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. *J Hypertens* 2003; **21**: 665–72. GL
 - 342) Osaki Y, Matsubayashi K, Yamasaki M, *et al*. Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. *Hypertens Res* 1998; **21**: 169–73. CT
 - 343) Blood Pressure in Acute Stroke Collaboration (BASC): Interventions for deliberating altering blood pressure in acute stroke. The Cochrane Library, Issue 3, 2003. Update Software, Oxford, 2003.
 - 344) The National Institute of Neurological Disorders and Stroke: Proceedings of national symposium on rapid identification and treatment of acute stroke. NIH publication 1997; No 97–4239: 1–183.
 - 345) Adams HP, del Zoppo G, Alberts MJ, *et al*; American Heart Association. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. *Stroke* 2007; **38**: 1655–711. GL
 - 346) Schrader J, Lüders S, Kulschewski A, *et al*; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of

- Acute Candesartan Cilexetil Therapy in Stroke Survivors. *Stroke* 2003; **34**: 1699–703. RT
- 347) Broderick J, Connolly S, Feldmann E, *et al*; American Heart Association. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. *Stroke* 2007; **38**: 2001–23. GL
- 348) Anderson CS, Huang Y, Wang JG, *et al*; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. *Lancet Neurol* 2008; **7**: 391–9. RT
- 349) Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. *Stroke* 1993; **24**: 1844–9.
- 350) The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. *Stroke* 1993; **24**: 543–8. RT
- 351) PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)* 1995; **108**: 710–7. RT
- 352) Eriksson S, *et al*. Atenolol in secondary prevention after stroke. *Cerebrovasc Dis* 1995; **5**: 21–5.
- 353) Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000; **342**: 145–53. RT
- 354) Schrader J, Lüders S, Kulschewski A, *et al*; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). *Stroke* 2005; **36**: 1218–26. RT
- 355) Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. *Stroke* 2003; **34**: 2741–8. MA
- 356) Yusuf S, Diener HC, Sacco RL, *et al*; PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med* 2008; **359**: 1225–37. RT
- 357) Sacco RL, Adams R, Albers G, *et al*; American Heart Association. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Stroke* 2006; **37**: 577–617. GL
- 358) Rothwell PM, Howard SC, Spence JD; Carotid Endarterectomy Trialists' Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. *Stroke* 2003; **34**: 2583–90. MA
- 359) Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M; Warfarin–Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. *Circulation* 2007; **115**: 2969–75. RT
- 360) Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. *Stroke* 1998; **29**: 1806–9. OS
- 361) 海老原進一郎, 鈴木則宏. 脳循環障害における脳循環・代謝. 脳血管障害. 五島雄一郎他編, 東京, ライフ・サイエンス 1980, p. 116–25.
- 362) 脳ドックの新ガイドライン作成委員会. 脳ドックのガイドライン2003 [internet]. 日本脳ドック学会, 2003. 参照日 2008年6月13日, <http://www.snh.or.jp/jsbd/pdf/guideline2003.pdf>. GL
- 363) 篠原幸人, 吉本高志, 福内靖男, 石神重信, 脳卒中合同ガイドライン委員会. 脳卒中治療ガイドライン2004. 東京, 協和企画, 2004. GL
- 364) Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med* 2003; **348**: 1215–22. OS
- 365) Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J. Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. *Stroke* 2000; **31**: 1646–50. CT
- 366) Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. *Stroke* 2002; **33**: 1536–40. CT
- 367) Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. *Cerebrovasc Dis* 2003; **16**: 280–5.

- 368) Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J; PROGRESS CT Substudy Investigators. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. *Hypertens Res* 2004; **27**: 147–56. RT
- 369) Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kimura J. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. *Stroke* 1998; **29**: 570–6. OS
- 370) Kario K, Pickering TG, Matsuo T, Hoshida S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. *Hypertension* 2001; **38**: 852–7. OS
- 371) Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. *Lancet* 2001; **358**: 1305–15. MA
- 372) Moser M, Hebert P, Hennekens CH. An overview of the meta-analyses of the hypertension treatment trials. *Arch Intern Med* 1991; **151**: 1277–9. MA
- 373) Pitt B, Byington RP, Furberg CD, *et al*; PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation* 2000; **102**: 1503–10. RT
- 374) Kondo J, Sone T, Tsuboi H, *et al*. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. *Am Heart J* 2003; **146**: E20. RT
- 375) Yui Y, Sumiyoshi T, Kodama K, *et al*; Japan Multicenter Investigation for Cardiovascular Diseases–B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases–B (JMIB–B) randomized trial. *Hypertens Res* 2004; **27**: 181–91. RT
- 376) Sacks FM, Pfeffer MA, Moye LA, *et al*; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996; **335**: 1001–9. RT
- 377) Messerli FH, Mancia G, Conti CR, *et al*. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med* 2006; **144**: 884–93. OS
- 378) Thune JJ, Signorovitch J, Kober L, *et al*. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. *Hypertension* 2008; **51**: 48–54. OS
- 379) Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. *J Hypertens* 2006; **24**: 2131–41. MA
- 380) Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. *J Am Coll Cardiol* 2007; **50**: 563–72. RV
- 381) Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. *N Engl J Med* 1985; **313**: 1055–8. RT
- 382) Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001; **357**: 1385–90. RT
- 383) The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1988; **319**: 385–92. RT
- 384) Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. *Am J Cardiol* 2004; **93**: 969–73. RT
- 385) Yui Y, Shinoda E, Kodama K, *et al*; Japan Multicenter Investigation for Cardiovascular Diseases B (JMIB–B) Study Group. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIB–B substudy). *J Hypertens* 2007; **25**: 2019–26. RT
- 386) Ishikawa K, Nakai S, Takenaka T, *et al*; Secondary Prevention Group. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. *Circulation* 1997; **95**: 2368–73. CT
- 387) Pfeffer MA, Braunwald E, Moyé LA, *et al*; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. *N Engl J Med* 1992; **327**: 669–77. RT
- 388) Pfeffer MA, McMurray JJ, Velazquez EJ, *et al*; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;

- 349: 1893–906. RT
- 389) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A; JCARE-GENERAL Investigators. Characteristics and outcomes of patients with heart failure in general practices and hospitals. *Circ J* 2007; **71**: 449–54. OS
- 390) Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. *JAMA* 1970; **213**: 1143–52. RT
- 391) The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991; **325**: 293–302. RT
- 392) The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992; **327**: 685–91. RT
- 393) Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001; **345**: 1667–75. RT
- 394) Pfeffer MA, Swedberg K, Granger CB, *et al*; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003; **362**: 759–66. RT
- 395) Granger CB, McMurray JJ, Yusuf S, *et al*; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003; **362**: 772–6. RT
- 396) Yusuf S, Pfeffer MA, Swedberg K, *et al*; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; **362**: 777–81. RT
- 397) Packer M, Bristow MR, Cohn JN, *et al*; U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996; **334**: 1349–55. RT
- 398) Hjalmarson A, Goldstein S, Fagerberg B, *et al*; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). *JAMA* 2000; **283**: 1295–302. RT
- 399) CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; **353**: 9–13. RT
- 400) Packer M, Coats AJ, Fowler MB, *et al*; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; **344**: 1651–8. RT
- 401) Hunt SA, Baker DW, Chin MH, *et al*; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. *Circulation* 2001; **104**: 2996–3007. GL
- 402) Packer M, O'Connor CM, Ghali JK, *et al*; Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1996; **335**: 1107–14. RT
- 403) Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990; **322**: 1561–6. OS
- 404) Verdecchia P, Schillaci G, Borgioni C, *et al*. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation* 1998; **97**: 48–54. OS
- 405) Wachtell K, Okin PM, Olsen MH, *et al*. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. *Circulation* 2007; **116**: 700–5. RT
- 406) Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *Am J Med* 2003; **115**: 41–6. MA
- 407) Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left

- ventricular mass and diastolic function in patients with essential hypertension. *Hypertens Res* 2002; **25**: 837–42. RT
- 408) Taniguchi I, Kawai M, Date T, *et al.* Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. *Circ J* 2006; **70**: 995–1000. RT
- 409) Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ; The Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. *Circulation* 1997; **95**: 2007–14. RT
- 410) Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med* 1995; **98**: 476–84. OS
- 411) Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002; **113**: 359–64. OS
- 412) Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998; **82**: 2N–9N. OS
- 413) Okin PM, Wachtell K, Devereux RB, *et al.* Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. *JAMA* 2006; **296**: 1242–8. OS
- 414) Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC; RACE Investigators. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. *Eur Heart J* 2007; **28**: 741–51. RT
- 415) Lip GY, Frison L, Grind M; SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. *Eur Heart J* 2007; **28**: 752–9. OS
- 416) Wachtell K, Lehto M, Gerdts E, *et al.* Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol* 2005; **45**: 712–9. RT
- 417) Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. *Am Heart J* 2006; **152**: 217–22. MA
- 418) Healey JS, Baranchuk A, Crystal E, *et al.* Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol* 2005; **45**: 1832–9. MA
- 419) Hirayama Y, Atarashi H, Kobayashi Y, *et al.* Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. *Circ J* 2005; **69**: 671–6. OS
- 420) Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. *Hypertens Res* 2007; **30**: 535–40. OS
- 421) Imai E, Horio M, Yamagata K, *et al.* GFR decline rate in Japanese general population: A longitudinal 10 year follow-up study. *Hypertens Res* 2008; **31**: 435–43. OS
- 422) Bakris GL, Williams M, Dworkin L, *et al.*; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. *Am J Kidney Dis* 2000; **36**: 646–61. GL
- 423) Klag MJ, Whelton PK, Randall BL, *et al.* Blood pressure and end-stage renal disease in men. *N Engl J Med* 1996; **334**: 13–8. OS
- 424) Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. *Hypertension* 2003; **41**: 1341–5. OS
- 425) The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 1997; **349**: 1857–63. RT
- 426) de Zeeuw D, Remuzzi G, Parving HH, *et al.* Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int* 2004; **65**: 2309–20. RT
- 427) Keane WF, Brenner BM, de Zeeuw D, *et al.*; RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. *Kidney Int* 2003; **63**: 1499–507. OS
- 428) Keith DS, Nichols GA, Gullion CM, Brown JB, Smith

- DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 2004; **164**: 659–63. OS
- 429) Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; **351**: 1296–305. OS
- 430) Levey AS, Coresh J, Balk E, *et al*; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003; **139**: 137–47. GL
- 431) Hillege HL, Girbes AR, de Kam PJ, *et al*. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 2000; **102**: 203–10. RT
- 432) Anavekar NS, McMurray JJ, Velazquez EJ, *et al*. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 2004; **351**: 1285–95. RT
- 433) Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med* 2001; **134**: 629–36. CT
- 434) Ruilope LM, Salvetti A, Jamerson K, *et al*. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. *J Am Soc Nephrol* 2001; **12**: 218–25. RT
- 435) Manjunath G, Tighiouart H, Coresh J, *et al*. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Kidney Int* 2003; **63**: 1121–9. OS
- 436) Manjunath G, Tighiouart H, Ibrahim H, *et al*. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. *J Am Coll Cardiol* 2003; **41**: 47–55. OS
- 437) Weiner DE, Tabatabai S, Tighiouart H, *et al*. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. *Am J Kidney Dis* 2006; **48**: 392–401. MA
- 438) Ohtake T, Kobayashi S, Moriya H, *et al*. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. *J Am Soc Nephrol* 2005; **16**: 1141–8. OS
- 439) Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 1984; **310**: 356–60. OS
- 440) Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 2003; **63**: 225–32. RT
- 441) Gerstein HC, Mann JF, Yi Q, *et al*; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; **286**: 421–6. OS
- 442) Hillege HL, Fidler V, Diercks GF, *et al*; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; **106**: 1777–82. OS
- 443) Wada M, Nagasawa H, Kurita K, *et al*. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. *J Neurol Sci* 2007; **255**: 27–34. OS
- 444) Ibsen H, Olsen MH, Wachtell K, *et al*. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. *Diabetes Care* 2006; **29**: 595–600. CT
- 445) Coresh J, Selvin E, Stevens LA, *et al*. Prevalence of chronic kidney disease in the United States. *JAMA* 2007; **298**: 2038–47. OS
- 446) Yokoyama H, Kawai K, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). *Diabetes Care* 2007; **30**: 989–92. OS
- 447) Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. *Nat Clin Pract Nephrol* 2007; **3**: 428–38. RV
- 448) Pohl MA, Blumenthal S, Cordonnier DJ, *et al*. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. *J Am Soc Nephrol* 2005; **16**: 3027–37. CT
- 449) Araki S, Haneda M, Koya D, *et al*. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. *Diabetes* 2007; **56**: 1727–30. OS

- 450) Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A; Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). *Diabetes Care* 2007; **30**: 1581–3. CT
- 451) Makino H, Haneda M, Babazono T, *et al*; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. *Diabetes Care* 2007; **30**: 1577–8. RT
- 452) Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. *Hypertens Res* 2007; **30**: 325–34. RT
- 453) Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. *Kidney Int* 2004; **65**: 1870–6. OS
- 454) Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. *Kidney Int* 2002; **62**: 956–62. OS
- 455) Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int* 2001; **59**: 1498–509. OS
- 456) Orth SR. Smoking and the kidney. *J Am Soc Nephrol* 2002; **13**: 1663–72.
- 457) Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. *Kidney Int* 2006; **69**: 2057–63. OS
- 458) 日本腎臓学会. 腎疾患患者の生活指導・食事療法に関するガイドライン. 日腎会誌1997; **39**: 1–37. GL
- 459) 日本腎臓学会企画委員会小委員会「食事療法ガイドライン改訂委員会」. 慢性腎臓病に対する食事療法基準2007年版. 日腎会誌2007; **49**: 871–8. GL
- 460) Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. *Ann Intern Med* 1996; **124**: 627–32. MA
- 461) Levey AS, Greene T, Beck GJ, *et al*; Modification of Diet in Renal Disease Study group. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? *J Am Soc Nephrol* 1999; **10**: 2426–39. CT
- 462) Casas JP, Chua W, Loukogeorgakis S, *et al*. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet* 2005; **366**: 2026–33. MA
- 463) Wright JT, Bakris G, Greene T, *et al*; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002; **288**: 2421–31. RT
- 464) Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. *Am J Kidney Dis* 2007; **49**: 12–26. RV
- 465) PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. *J Hypertens* 2002; **20**: 729–37. RT
- 466) Hollenberg NK, Parving HH, Viberti G, *et al*. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. *J Hypertens* 2007; **25**: 1921–6. RT
- 467) MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. *Am J Kidney Dis* 2006; **48**: 8–20. MA
- 468) Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. *Ann Intern Med* 2008; **148**: 30–48. MA
- 469) Lewis EJ, Hunsicker LG, Clarke WR, *et al*; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; **345**: 851–60. RT
- 470) Solomon SD, Rice MM, A Jablonski K, *et al*; Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. *Circulation* 2006; **114**: 26–31. RT
- 471) Ruggenti P, Perna A, Remuzzi G; GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. *Kidney Int* 2003; **63**: 2254–61. RT

- 472) de Zeeuw D. Albuminuria, just a marker for cardiovascular disease, or is it more? *J Am Soc Nephrol* 2005; **16**: 1883–5.
- 473) Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999; **33**: 1004–10. GL
- 474) Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 2004; **43**: S1–290. GL
- 475) Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* 2003; **41**: 64–8. CT
- 476) Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. *Kidney Int* 2006; **70**: 2116–23. RT
- 477) Ruggenti P, Perna A, Loriga G, *et al*; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet* 2005; **365**: 939–46. RT
- 478) Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. *Diabetes Res Clin Pract* 2001; **54**: 191–201. RT
- 479) Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. *Am J Hypertens* 2003; **16**: 116–22. RT
- 480) Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. *Kidney Int* 2006; **70**: 151–6. RT
- 481) Ogawa S, Mori T, Nako K, Ito S. A combination therapy of renin-angiotensin system inhibitors and calcium channel blocker, Azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. *Hypertens Res* 2008; **31**: 1147–55.
- 482) Zager PG, Nikolic J, Brown RH, *et al*; Medical Directors of Dialysis Clinic, Inc. “U” curve association of blood pressure and mortality in hemodialysis patients. *Kidney Int* 1998; **54**: 561–9. OS
- 483) Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. *Kidney Int* 2000; **58**: 2147–54. OS
- 484) Iseki K, Miyasato F, Tokuyama K, *et al*. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. *Kidney Int* 1997; **51**: 1212–7. OS
- 485) Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. *Clin J Am Soc Nephrol* 2007; **2**: 1228–34. OS
- 486) Moriya H, Oka M, Maesato K, *et al*. Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. *Clin J Am Soc Nephrol* 2008; **3**: 416–22. OS
- 487) Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. *Kidney Int* 2002; **61**: 717–26. OS
- 488) Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney Int* 2004; **66**: 1212–20.
- 489) Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. *Circulation* 2001; **103**: 987–92. CT
- 490) Kitahara T, Ono K, Tsuchida A, *et al*. Impact of brachial–ankle pulse wave velocity and ankle–brachial blood pressure index on mortality in hemodialysis patients. *Am J Kidney Dis* 2005; **46**: 688–96. OS
- 491) London GM, Pannier B, Guerin AP, *et al*. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. *J Am Soc Nephrol* 2001; **12**: 2759–67. OS
- 492) Bragg-Gresham JL, Fissell RB, Mason NA, *et al*. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). *Am J Kidney Dis* 2007; **49**: 426–31. OS
- 493) Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. *Kidney Int* 2002; **61**: 2157–64.
- 494) Foley RN, Herzog CA, Collins AJ; United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. *Kidney Int* 2002; **62**: 1784–90. OS
- 495) Efrati S, Zaidenstein R, Dishy V, *et al*. ACE inhibitors and survival of hemodialysis patients. *Am J Kidney Dis* 2002; **40**: 1023–9. OS

- 496) Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. *Nephron* 2002; **90**: 256–61. RT
- 497) Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. *Adv Perit Dial* 2003; **19**: 59–66. RT
- 498) Ichihara A, Hayashi M, Kaneshiro Y, *et al.* Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. *Am J Kidney Dis* 2005; **45**: 866–74. RT
- 499) Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. *Am J Kidney Dis* 2004; **43**: 1056–64. RT
- 500) 大動脈瘤・大動脈解離診療ガイドライン (2006年改訂版) *Circ J* 2006; **70**: 1569–646. GL
- 501) Ashton HA, Buxton MJ, Day NE, *et al*; Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet* 2002; **360**: 1531–9. RT
- 502) Brewster DC, Cronenwett JL, Hallett JW, Johnston KW, Krupski WC, Matsumura JS; Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. *J Vasc Surg* 2003; **37**: 1106–17. GL
- 503) Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term β -adrenergic blockade in Marfan's syndrome. *N Engl J Med* 1994; **330**: 1335–41. RT
- 504) Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med* 2008; **358**: 2787–95.
- 505) Lacro RV, Dietz HC, Wruck LM, *et al*; Pediatric Heart Network Investigators. Rationale and design of a randomized clinical trial of β -blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. *Am Heart J* 2007; **154**: 624–31.
- 506) Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. *Lancet* 2006; **368**: 659–65. OS
- 507) MacSweeney ST, Ellis M, Worrell PC, Greenhalgh RM, Powell JT. Smoking and growth rate of small abdominal aortic aneurysms. *Lancet* 1994; **344**: 651–2.
- 508) Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. *N Engl J Med* 2002; **347**: 1941–51. RV
- 509) Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg* 2007; **45**: S5–67. GL
- 510) Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med* 1991; **151**: 1769–76. MA
- 511) Iimura O. Insulin resistance and hypertension in Japanese. *Hypertens Res* 1996; **19 Suppl 1**: S1–8. RV
- 512) American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. *Diabetes Care* 1989; **12**: 573–9. GL
- 513) UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; **317**: 713–20. RT
- 514) Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. *Ann Intern Med* 1993; **118**: 577–81. RT
- 515) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2002; **25**: S5–20. GL
- 516) 大西浩文, 齋藤重幸, 島本和明, 端野・壮瞥町研究レビュー 2007. *Ther Res* 2007; **28**: 513–25. RV
- 517) Iimura O, Shimamoto K, Matsuda K, *et al.* Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. *Am J Hypertens* 1995; **8**: 353–7. CT
- 518) The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. *Lancet* 1997; **349**: 1787–92. RT
- 519) J-MIND 研究グループ, 鹿住敏, 芳野原, 吉川隆一, 馬場

- 茂明. 糖尿病性腎症の発症・進展に対するCa拮抗薬とACE阻害薬との長期効果の比較. 糖尿病1999; **42**: 5225.
- 520) Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001; **345**: 870–8. RT
- 521) Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 2002; **106**: 672–8. RT
- 522) Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/ β -blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. *Diabetes Care* 2001; **24**: 2091–6. RT
- 523) Tuomilehto J, Rastenyte D, Birkenhäger WH, *et al*. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *N Engl J Med* 1999; **340**: 677–84. RT
- 524) Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998; **338**: 645–52. RT
- 525) Tatti P, Pahor M, Byington RP, *et al*. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; **21**: 597–603. RT
- 526) Leenen FH, Nwachuku CE, Black HR, *et al*; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Hypertension* 2006; **48**: 374–84. RT
- 527) Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. *Kidney Int* 2008; **73**: 1303–9. RT
- 528) Matsuzaki M, Kita T, Mabuchi H, *et al*; J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. *Circ J* 2002; **66**: 1087–95. OS
- 529) Sever PS, Dahlöf B, Poulter NR, *et al*; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; **361**: 1149–58. RT
- 530) 厚生省保健医療局健康増進栄養課. 国民栄養の現状. 平成2年度国民栄養調査成績. 第一出版. 1992; p121.
- 531) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486–97. GL
- 532) 大西浩文, 他: 地域一般住民における腹部肥満およびメタボリックシンドロームからの2型糖尿病発症リスクに関する検討—端野・壮瞥町研究より. 糖尿病 2007; **49**: s–50.
- 533) Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. *Am J Respir Crit Care Med* 2001; **164**: 2147–65. RV
- 534) Eguchi K, Kario K, Hoshida S, Ishikawa J, Morinari M, Shimada K. Nocturnal hypoxia is associated with silent cerebrovascular disease in a high-risk Japanese community-dwelling population. *Am J Hypertens* 2005; **18**: 1489–95. OS
- 535) Wolk R, Somers VK. Sleep and the metabolic syndrome. *Exp Physiol* 2007; **92**: 67–78. RV
- 536) Sasanabe R, Banno K, Otake K, *et al*. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. *Hypertens Res* 2006; **29**: 315–22. OS
- 537) Shiina K, Tomiyama H, Takata Y, *et al*. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. *Hypertens Res* 2006; **29**: 433–41. OS
- 538) Endo S, Mataka S, Kurosaki N. Cephalometric evaluation of craniofacial and upper airway structures in Japanese patients with obstructive sleep

- apnea. *J Med Dent Sci* 2003; **50**: 109–20. OS
- 539) Sharafkhaneh A, Giray N, Richardson P, Young T, Hirshkowitz M. Association of psychiatric disorders and sleep apnea in a large cohort. *Sleep* 2005; **28**: 1405–11. OS
- 540) Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. *Hypertension* 2003; **42**: 1067–74. RV
- 541) Umlauf MG, Chasens ER, Greevy RA, Arnold J, Burgio KL, Pillion DJ. Obstructive sleep apnea, nocturia and polyuria in older adults. *Sleep* 2004; **27**: 139–44. OS
- 542) Logan AG, Perlikowski SM, Mente A, *et al.* High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens* 2001; **19**: 2271–7. OS
- 543) Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest* 1995; **96**: 1897–904. OS
- 544) Pickering TG, Kario K. Nocturnal non-dipping: what does it augur? *Curr Opin Nephrol Hypertens* 2001; **10**: 611–6. RV
- 545) Kishimoto A, Tochikubo O, Ohshige K. Relation between nocturnal arterial oxygen desaturation and morning blood pressure. *Clin Exp Hypertens* 2007; **29**: 51–60. CT
- 546) Noda A, Nakata S, Koike Y, *et al.* Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. *Hypertens Res* 2007; **30**: 669–76. RT
- 547) Møller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. *Am J Hypertens* 2003; **16**: 274–80. CT
- 548) Schulz R, Mahmoudi S, Hattar K, *et al.* Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. *Am J Respir Crit Care Med* 2000; **162**: 566–70.
- 549) Yamauchi M, Nakano H, Maekawa J, *et al.* Oxidative stress in obstructive sleep apnea. *Chest* 2005; **127**: 1674–9. OS
- 550) Shamsuzzaman AS, Winnicki M, Lanfranchi P, *et al.* Elevated C-reactive protein in patients with obstructive sleep apnea. *Circulation* 2002; **105**: 2462–4. CT
- 551) Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. *Am J Physiol Heart Circ Physiol* 2000; **279**: H234–7. CT
- 552) Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. *Am J Respir Crit Care Med* 2002; **165**: 670–6. OS
- 553) Shirasaki O, Yamashita S, Kawara S, *et al.* A new technique for detecting sleep apnea-related “mid-night” surge of blood pressure. *Hypertens Res* 2006; **29**: 695–702.
- 554) Amin R, Somers VK, McConnell K, *et al.* Activity-adjusted 24-hour ambulatory blood pressure and cardiac remodeling in children with sleep disordered breathing. *Hypertension* 2008; **51**: 84–91. CT
- 555) Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. *Hypertension* 2007; **50**: 417–23. MA
- 556) Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. *Cochrane Database Syst Rev* 2006; **3**: CD001106. MA
- 557) Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. *Chest* 2005; **127**: 2076–84. OS
- 558) Marin JM, Carrizo SJ, Vicente E, Agustí AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet*; **365**: 1046–53. OS
- 559) Barbé F, Mayoralas LR, Duran J, *et al.* Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. *Ann Intern Med* 2001; **134**: 1015–23. RT
- 560) Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. *Eur Respir J* 2006; **27**: 1229–35. RT
- 561) Kraiczi H, Hedner J, Peker Y, Grote L. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 2000; **161**: 1423–8. RT
- 562) Pelttari LH, Hietanen EK, Salo TT, Kataja MJ, Kantola IM. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. *Am J Hypertens* 1998; **11**: 272–9. RT

- 563) Bucca CB, Brussino L, Battisti A, *et al.* Diuretics in obstructive sleep apnea with diastolic heart failure. *Chest* 2007; **132**: 440–6. OS
- 564) Cicolin A, Mangiardi L, Mutani R, Bucca C. Angiotensin-converting enzyme inhibitors and obstructive sleep apnea. *Mayo Clin Proc* 2006; **81**: 53–5. OS
- 565) Hirota SA, Janssen LJ. Sodium and asthma: something borrowed, something new? *Am J Physiol Lung Cell Mol Physiol* 2007; **293**: L1369–73.
- 566) Arai T, Yasuda Y, Toshima S, Yoshimi N, Kashiki Y. ACE inhibitors and pneumonia in elderly people. *Lancet* 1998; **352**: 1937–8.
- 567) Okaishi K, Morimoto S, Fukuo K, *et al.* Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. *Am J Hypertens* 1999; **12**: 778–83. CT
- 568) Andreas S, Herrmann-Lingen C, Raupach T, *et al.* Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. *Eur Respir J* 2006; **27**: 972–9. RT
- 569) Cheng JW, Zhu L, Gu MJ, Song ZM. Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. *World J Gastroenterol* 2003; **9**: 1836–9. MA
- 570) Yokohama S, Yoneda M, Haneda M, *et al.* Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. *Hepatology* 2004; **40**: 1222–5. OS
- 571) 高尿酸血症・痛風の治療ガイドライン作成委員会. 高尿酸血症・痛風の治療ガイドライン (第1版) 東京, 日本痛風・核酸代謝学会. 2002. p79. GL
- 572) Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. *J Pharmacol Exp Ther* 2007; **320**: 211–7.
- 573) Enomoto A, Kimura H, Chairoungdua A, *et al.* Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature* 2002; **417**: 447–52.
- 574) Høiegggen A, Alderman MH, Kjeldsen SE, *et al*; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Kidney Int* 2004; **65**: 1041–9. RT
- 575) Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. *Lancet* 2000; **355**: 175–80.
- 576) Rastas S, Pirttilä T, Viramo P, *et al.* Association between blood pressure and survival over 9 years in a general population aged 85 and older. *J Am Geriatr Soc* 2006; **54**: 912–8. OS
- 577) van Bommel T, Gussekloo J, Westendorp RG, Blauw GJ. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years. *J Hypertens* 2006; **24**: 287–92. OS
- 578) Fagard RH, Staessen JA, Thijs L, *et al.* On-treatment diastolic blood pressure and prognosis in systolic hypertension. *Arch Intern Med* 2007; **167**: 1884–91. OS
- 579) Amery A, Birkenhäger W, Brixko P, *et al.* Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. *Lancet* 1985; **1**: 1349–54. RT
- 580) Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekblom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) *Lancet* 1991; **338**: 1281–5. RT
- 581) MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. *BMJ* 1992; **304**: 405–12. RT
- 582) Lithell H, Hansson L, Skoog I, *et al*; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003; **21**: 875–86. RT
- 583) Lithell H, Hansson L, Skoog I, *et al*; SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE) ; outcomes in patients not receiving add-on therapy after randomization. *J Hypertens* 2004; **22**: 1605–12. RT
- 584) SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991; **265**: 3255–64. RT
- 585) Staessen JA, Fagard R, Thijs L, *et al*; The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet* 1997; **350**: 757–64. RT
- 586) Liu L, Wang JG, Gong L, Liu G, Staessen JA; Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. *J Hypertens* 1998; **16**: 1823–9. CT
- 587) Gong L, Zhang W, Zhu Y, *et al.* Shanghai trial of nifedipine in the elderly (STONE). *J Hypertens* 1996; **14**: 1237–45. CT
- 588) Insua JT, Sacks HS, Lau TS, *et al.* Drug treatment of hypertension in the elderly: a meta-analysis. *Ann Intern Med* 1994; **121**: 355–62. MA

- 589) Black HR, Elliott WJ, Weber MA, *et al.* One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. *Hypertension* 2001; **38**: 1118–23. RT
- 590) JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Hypertens Res* 2008; **31**: 2115–27. RT
- 591) Perry HM, Davis BR, Price TR, *et al.*; Systolic Hypertension in the Elderly Program (SHEP) Co-operative Research Group. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 2000; **284**: 465–71. RT
- 592) Kjeldsen SE, Kolloch RE, Leonetti G, *et al.* Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. *Hypertension Optimal Treatment*. *J Hypertens* 2000; **18**: 629–42. RT
- 593) Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. *Arch Intern Med* 1999; **159**: 2004–9. OS
- 594) Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. *Am J Hypertens* 2000; **13**: 461–7. CT
- 595) Motoyama M, Sunami Y, Kinoshita F, *et al.* Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. *Med Sci Sports Exerc* 1998; **30**: 818–23.
- 596) Hiwada K, Ogihara T, Matsumoto M, *et al.* Guidelines for hypertension in the elderly—1999 revised version. Ministry of Health and Welfare of Japan. *Hypertens Res* 1999; **22**: 231–59. GL
- 597) Forette F, Seux ML, Staessen JA, *et al.* Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet* 1998; **352**: 1347–51. RT
- 598) Kjeldsen SE, Dahlöf B, Devereux RB, *et al.*; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 2002; **288**: 1491–8. CT
- 599) Papademetriou V, Farsang C, Elmfeldt D, *et al.*; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). *J Am Coll Cardiol* 2004; **44**: 1175–80. CT
- 600) Wing LM, Reid CM, Ryan P, *et al.*; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med* 2003; **348**: 583–92. RT
- 601) Turnbull F, Neal B, Ninomiya T, *et al.*; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* 2008; **336**: 1121–3. MA
- 602) Berthet K, Neal BC, Chalmers JP, *et al.*; Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. *Blood Press* 2004; **13**: 7–13. RT
- 603) Lindholm LH, Hansson L, Ekbom T, *et al.*; STOP Hypertension-2 Study Group. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. *J Hypertens* 2000; **18**: 1671–5. RT
- 604) Mancia G, Brown M, Castaigne A, *et al.*; INSIGHT. Outcomes with nifedipine GITS or Co-amlozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). *Hypertension* 2003; **41**: 431–6. RT
- 605) Whelton PK, Barzilay J, Cushman WC, *et al.*; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med* 2005; **165**: 1401–9. RT
- 606) Khan NA, Hemmelgarn B, Padwal R, *et al.*; Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2—therapy. *Can J Cardiol* 2007; **23**: 539–50. GL
- 607) Mosca L, Banka CL, Benjamin EJ, *et al.*; Expert Panel/ Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *J Am Coll Cardiol* 2007; **49**: 1230–50. GL
- 608) Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. *Nat Clin Pract Nephrol* 2007; **3**: 613–22. RV

- 609) 妊娠高血圧症候群の定義と分類. 日産婦誌. 2004; 56: 12–3. GL
- 610) Churchill D, Perry IJ, Beevers DG. Ambulatory blood pressure in pregnancy and fetal growth. *Lancet* 1997; 349: 7–10. OS
- 611) Penny JA, Halligan AW, Shennan AH, *et al.* Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? *Am J Obstet Gynecol* 1998; 178: 521–6. OS
- 612) Waugh J, Perry IJ, Halligan AW, *et al.* Birth weight and 24-hour ambulatory blood pressure in nonproteinuric hypertensive pregnancy. *Am J Obstet Gynecol* 2000; 183: 633–7. OS
- 613) Staessen JA, Asmar R, De Buyzere M, *et al.* Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II: blood pressure measurement and cardiovascular outcome. *Blood Press Monit* 2001; 6: 355–70. GL
- 614) Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev* 2001; CD002252. RV
- 615) Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet* 2005; 365: 785–99. RV
- 616) Sibai BM. Chronic hypertension in pregnancy. *Obstet Gynecol* 2002; 100: 369–77. RV
- 617) von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated meta-regression analysis. *J Obstet Gynaecol Can* 2002; 24: 941–5. MA
- 618) Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. *N Engl J Med* 1996; 335: 226–32. OS
- 619) Easterling TR, Carr DB, Davis C, Diederichs C, Brateng DA, Schmucker B. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. *Obstet Gynecol* 2000; 96: 956–61. OS
- 620) Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia before term. *Cochrane Database Syst Rev* 2002; CD003106. RV
- 621) von Dadelszen P, Menzies J, Gilgoff S, *et al.* Evidence-based management for preeclampsia. *Front Biosci* 2007; 12: 2876–89. RV
- 622) Magee LA, Schick B, Donnerfeld AE, *et al.* The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol* 1996; 174: 823–8. CT
- 623) Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol* 2000; 183: S1–S22. GL
- 624) Aali BS, Nejad SS. Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. *Acta Obstet Gynecol Scand* 2002; 81: 25–30. RT
- 625) Hanff LM, Vulto AG, Bartels PA, *et al.* Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset preeclamptic patients. *J Hypertens* 2005; 23: 2319–26.
- 626) Roberts JM, Pearson G, Cutler J, Lindheimer M; NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. *Hypertension* 2003; 41: 437–45. RV
- 627) Montán S. Drugs used in hypertensive diseases in pregnancy. *Curr Opin Obstet Gynecol* 2004; 16: 111–5. RV
- 628) Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. *Am J Med* 1994; 96: 451–6. MA
- 629) Cooper WO, Hernandez-Diaz S, Arbogast PG, *et al.* Major congenital malformations after first-trimester exposure to ACE inhibitors. *N Engl J Med* 2006; 354: 2443–51. OS
- 630) From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. *JAMA* 1997; 277: 1193–4.
- 631) Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. *Cochrane Database Syst Rev* 2007; CD004451. RV
- 632) Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. *Cochrane Database Syst Rev* 2007; CD004659. MA
- 633) Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 2003; CD000025. RV
- 634) Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
- 635) Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. *Hypertension* 2000; 35: 1000–1005. GL

- pertension 2004; **43**: 918–23. RV
- 636) Beale CM, Collins P. The menopause and the cardiovascular system. *Baillieres Clin Obstet Gynaecol* 1996; **10**: 483–513. RV
- 637) Oparil S. Hypertension in postmenopausal women: pathophysiology and management. *Curr Opin Nephrol Hypertens* 1995; **4**: 438–42. RV
- 638) Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. *J Hum Hypertens* 1998; **12**: 587–92. RV
- 639) Luoto R, Sharrett AR, Schreiner P, Sorlie PD, Arnett D, Ephross S. Blood pressure and menopausal transition: the Atherosclerosis Risk in Communities study (1987–95). *J Hypertens* 2000; **18**: 27–33. OS
- 640) Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. *Cardiovasc Res* 2002; **53**: 688–708. RV
- 641) Pines A, Fisman EZ. Hypertension in menopausal women—a special case, for special treatment? *Gynecol Endocrinol* 2001; **15**: 397–405. RV
- 642) Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. *Curr Hypertens Rep* 2002; **4**: 464–70. RV
- 643) Rossouw JE, Anderson GL, Prentice RL, *et al*; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002; **288**: 321–33. RT
- 644) Grady D, Herrington D, Bittner V, *et al*; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA* 2002; **288**: 49–57. RT
- 645) Scuteri A, Bos AJ, Brant LJ, Talbot L, Lakatta EG, Fleg JL. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. *Ann Intern Med* 2001; **135**: 229–38. OS
- 646) Chasan-Taber L, Willett WC, Manson JE, *et al*. Prospective study of oral contraceptives and hypertension among women in the United States. *Circulation* 1996; **94**: 483–9. OS
- 647) Anderson GL, Limacher M, Assaf AR, *et al*; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004; **291**: 1701–12. RT
- 648) Miller JA, Cherney DZ, Duncan JA, *et al*. Gender differences in the renal response to renin-angiotensin system blockade. *J Am Soc Nephrol* 2006; **17**: 2554–60. CT
- 649) Tominaga T, Suzuki H, Ogata Y, Matsukawa S, Saruta T. The role of sex hormones and sodium intake in postmenopausal hypertension. *J Hum Hypertens* 1991; **5**: 495–500.
- 650) Fernández-Vega F, Abellán J, Vegazo O, *et al*. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: Influence of hormone replacement therapy. *Kidney Int Suppl* 2002; **62**: 36–41. OS
- 651) Deroo BJ, Korach KS. Estrogen receptors and human disease. *J Clin Invest* 2006; **116**: 561–70. RV
- 652) Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet* 2005; **366**: 1797–803. OS
- 653) Pell JP, Smith GC, Walsh D. Pregnancy complications and subsequent maternal cerebrovascular events: a retrospective cohort study of 119,668 births. *Am J Epidemiol* 2004; **159**: 336–42. OS
- 654) Suzuki H, Watanabe Y, Arima H, Kobayashi K, Ohno Y, Kanno Y. Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. *Clin Exp Nephrol* 2008; **12**: 102–9. RV
- 655) Uchiyama M, Sakai K. Studies of blood pressures in school children in northern Japan. *Public Health* 1985; **99**: 18–22. OS
- 656) Tochikubo O, Sasaki O, Umemura S, Kaneko Y. Management of hypertension in high school students by using new salt titrator tape. *Hypertension* 1986; **8**: 1164–71. OS
- 657) 文部科学省: 平成19年度学校保健統計調査. [internet] 参照日 2008年10月16日. http://www.mext.go.jp/b_menu/toukei/001/h19.htm
- 658) National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004; **114**: 555–76. GL
- 659) 村田光範. 高血圧. 小児科臨床 1986; 39 (増刊号): 2977–2984.
- 660) Hashimoto N, Kawasaki T, Kikuchi T, Uchiyama M. Criteria of normal blood pressure and hypertension in Japanese preschool children. *J Hum Hypertens* 1997; **11**: 351–4. OS
- 661) 山内邦昭. 小児生活習慣病予防健診実施報告書 (平成5～11年度), (財) 予防医学事業中央会, 2002.

- 662) 内山聖, 菊池透, 山崎恒, 亀田一博, 樋浦誠. 日本人小児の
高血圧判定基準の検討. 厚生省子ども家庭総合研究事業
「子どものライフスタイルと生活習慣病に関する研究」, 厚
生科学研究「小児糖尿病・生活習慣病の発症要因, 治療,
予防に関する研究 (主任研究者: 松浦信夫)」平成12年度
研究報告書, 2001, pp74-75.
- 663) 吉永正夫. 思春期の生活習慣病の基準値 (暫定案) 作成に
関する研究. 厚生省科学研究費「幼児期・思春期における
生活習慣病の概念, 自然史, 診断基準の確立及び効果的介
入に関するコホート研究」(主任研究者: 吉永正夫), 平成
19年度研究報告書, 2008, pp13-22.
- 664) 菊池透, 長崎啓祐, 樋浦誠, 小川洋平, 田中幸恵, 内山聖.
小児肥満の疫学的アプローチ. 肥満研究 2004; 10: 12-17.
- 665) Kotani K, Nishida M, Yamashita S, *et al.* Two decades
of annual medical examinations in Japanese obese
children: do obese children grow into obese adults?
Int J Obes Relat Metab Disord 1997; 21: 912-21. OS
- 666) Hashimoto N, Kawasaki T, Kikuchi T, Takahashi H,
Uchiyama M. The relationship between the intrauter-
ine environment and blood pressure in 3-year-old
Japanese children. *Acta Paediatr* 1996; 85: 132-8. OS
- 667) Miura K, Nakagawa H, Tabata M, Morikawa Y,
Nishijo M, Kagamimori S. Birth weight, childhood
growth, and cardiovascular disease risk factors in
Japanese aged 20 years. *Am J Epidemiol* 2001; 153:
783-9. OS
- 668) Abe Y, Kikuchi T, Nagasaki K, *et al.* Lower birth
weight associated with current overweight status is
related with the metabolic syndrome in obese
Japanese children. *Hypertens Res* 2007; 30: 627-34. OS
- 669) Stabouli S, Kotsis V, Zakopoulos N. Ambulatory
blood pressure monitoring and target organ damage
in pediatrics. *J Hypertens* 2007; 25: 1979-86. RV
- 670) Uchiyama M. Risk factors for the development of
essential hypertension: long-term follow-up study in
junior high school students in Niigata, Japan. *J Hum
Hypertens* 1994; 8: 323-5. OS
- 671) Kawasaki T, Uezono K, Sanefuji M, *et al.* A 17-year
follow-up study of hypertensive and normotensive
male university students in Japan. *Hypertens Res*
2003; 26: 445-52. CT
- 672) Bao W, Threefoot SA, Srinivasan SR, Berenson GS.
Essential hypertension predicted by tracking of
elevated blood pressure from childhood to adult-
hood: the Bogalusa Heart Study. *Am J Hypertens* 1995;
8: 657-65. OS
- 673) Research Committee on Serum Lipid Level Survey
1990 in Japan. Current state of and recent trends in
serum lipid levels in the general Japanese popula-
tion. *J Atheroscler Thromb* 1996; 2: 122-32. OS
- 674) Leary SD, Ness AR, Smith GD, *et al.* Physical activity
and blood pressure in childhood: findings from a
population-based study. *Hypertension* 2008; 51: 92-8.
OS
- 675) Pickering TG, Shimbo D, Haas D. Ambulatory blood-
pressure monitoring. *N Engl J Med* 2006; 354: 2368-
74. RV
- 676) Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R.
Long-term risk of mortality associated with selective
and combined elevation in office, home, and ambula-
tory blood pressure. *Hypertension* 2006; 47: 846-53.
OS
- 677) Kario K. Clinician's manual on early morning risk
management in hypertension. Science Press, London,
pp1-68, 2004.
- 678) Obara T, Ohkubo T, Kikuya M, *et al.*; J-HOME Study
Group. Prevalence of masked uncontrolled and
treated white-coat hypertension defined according to
the average of morning and evening home blood
pressure value: from the Japan Home versus Office
Measurement Evaluation Study. *Blood Press Monit*
2005; 10: 311-6. OS
- 679) Tomiyama M, Horio T, Yoshii M, *et al.* Masked
hypertension and target organ damage in treated
hypertensive patients. *Am J Hypertens* 2006; 19: 880-
6. OS
- 680) Matsui Y, Eguchi K, Ishikawa J, Hoshida S, Shimada
K, Kario K. Subclinical arterial damage in untreated
masked hypertensive subjects detected by home
blood pressure measurement. *Am J Hypertens* 2007;
20: 385-91. CT
- 681) Björklund K, Lind L, Zethelius B, Andrén B, Lithell
H. Isolated ambulatory hypertension predicts cardio-
vascular morbidity in elderly men. *Circulation* 2003;
107: 1297-302. OS
- 682) Ishikawa J, Kario K, Eguchi K, *et al.*; J-MORE Group.
Regular alcohol drinking is a determinant of masked
morning hypertension detected by home blood
pressure monitoring in medicated hypertensive
patients with well-controlled clinic blood pressure:
the Jichi Morning Hypertension Research (J-MORE)
study. *Hypertens Res* 2006; 29: 679-86. OS
- 683) Mallion JM, Clerson P, Bobrie G, Genes N, Vaisse B,
Chatellier G. Predictive factors for masked hyperten-
sion within a population of controlled hypertensives.
J Hypertens 2006; 24: 2365-70. OS
- 684) Takagi T, Ohishi M, Ito N, *et al.* Evaluation of
morning blood pressure elevation and autonomic
nervous activity in hypertensive patients using
wavelet transform of heart rate variability. *Hypertens*

- Res 2006; **29**: 977–87. OS
- 685) Gosse P, Lasserre R, Minifié C, Lemetayer P, Clementy J. Blood pressure surge on rising. *J Hypertens* 2004; **22**: 1113–8. OS
- 686) Kuwajima I, Mitani K, Miyao M, Suzuki Y, Kuramoto K, Ozawa T. Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients: relation to arising time. *Am J Hypertens* 1995; **8**: 29–33. OS
- 687) Polónia J, Amado P, Barbosa L, et al. Morning rise, morning surge and daytime variability of blood pressure and cardiovascular target organ damage. A cross-sectional study in 743 subjects. *Rev Port Cardiol* 2005; **24**: 65–78. OS
- 688) Marfella R, Siniscalchi M, Portoghese M, et al. Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. *Hypertension* 2007; **49**: 784–91.
- 689) Shibuya Y, Ikeda T, Gomi T. Morning rise of blood pressure assessed by home blood pressure monitoring is associated with left ventricular hypertrophy in hypertensive patients receiving long-term antihypertensive medication. *Hypertens Res* 2007; **30**: 903–11. OS
- 690) Murakami S, Otsuka K, Kubo Y, et al. Repeated ambulatory monitoring reveals a Monday morning surge in blood pressure in a community-dwelling population. *Am J Hypertens* 2004; **17**: 1179–83. OS
- 691) Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. *J Hypertens* 2008; **26**: 1636–41. OS
- 692) Hoshide S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. *Hypertens Res* 2007; **30**: 143–9. OS
- 693) Li Y, Staessen JA, Lu L, Li LH, Wang GL, Wang JG. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. *Hypertension* 2007; **50**: 333–9. OS
- 694) Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. *Circulation* 1999; **100**: 1635–8. CT
- 695) Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. *Hypertension* 2008; **51**: 69–76. RT
- 696) Kario K, James GD, Marion R, Ahmed M, Pickering TG. The influence of work- and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women. *Hypertens Res* 2002; **25**: 499–506. OS
- 697) Yamasaki F, Schwartz JE, Gerber LM, Warren K, Pickering TG. Impact of shift work and race/ethnicity on the diurnal rhythm of blood pressure and catecholamines. *Hypertension* 1998; **32**: 417–23. OS
- 698) Kaplan NM. Hypertensive crises. in Kaplan's Clinical Hypertension (9th ed), Lippincott Williams & Wilkins, Baltimore, p311–324, 2006.
- 699) Rosei EA, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. *J Hypertens* 2006; **24**: 2482–5. RV
- 700) Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet* 2000; **356**: 411–7. RV
- 701) 循環器病の診断と治療に関するガイドライン (2004–2005年度合同研究班報告): 急性心不全治療ガイドライン (2006年改訂版) [internet], 2006 参照日 2008年6月13日. http://www.j-circ.or.jp/guideline/pdf/JCS2006_maruyama_h.pdf GL
- 702) Sesoko S, Akema N, Matsukawa T, Kaneko Y. Predisposing factors for the development of malignant essential hypertension. *Arch Intern Med* 1987; **147**: 1721–4. CT
- 703) Ohta Y, Tsuchihashi T, Ohya Y, et al. Trends in the pathophysiological characteristics of malignant hypertension. *Hypertens Res* 2001; **24**: 489–92. CT
- 704) Kawazoe N, Eto T, Abe I, et al. Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis. *Clin Nephrol* 1988; **29**: 53–7. OS
- 705) Kaplan NM. Functional somatic disease. in Clinical Hypertension (9th ed), Lippincott Williams & Wilkins, Baltimore, p451–453, 2006.
- 706) Mann SJ. Severe paroxysmal hypertension (pseudo-pheochromocytoma): understanding the cause and treatment. *Arch Intern Med* 1999; **159**: 670–4. OS
- 707) Fleisher LA, Beckman JA, Brown KA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice

- Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation* 2007; **116**: e418–99. GL
- 708) Herman WW, Konzelman JL, Prisant LM; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. New national guidelines on hypertension: a summary for dentistry. *J Am Dent Assoc* 2004; **135**: 576–84. GL
- 709) Tsuchihashi T, Takata Y, Kurokawa H, *et al*. Blood pressure response during dental surgery. *Hypertens Res* 1996; **19**: 189–94. OS
- 710) 尾前照雄. 高血圧症の病態と予後. 日内会誌 1985; **74**: 401–15.
- 711) 尾前照雄. 若年性高血圧症の病因・病態生理. 厚生省特定疾患若年性高血圧症調査研究班昭和52年度研究報告書. P45–53, 1978.
- 712) Rossi GP, Bernini G, Caliumi C, *et al*; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006; **48**: 2293–300. OS
- 713) Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? *Endocr J* 2007; **54**: 487–95. RV
- 714) Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens* 1994; **12**: 609–15. OS
- 715) Gifford RW. Evaluation of the hypertensive patients with emphasis on detecting curable causes. *Milbank Mem Fund Q* 1969; **47**: 170–86.
- 716) Bech K, Hilden T. The frequency of secondary hypertension. *Acta Med Scand* 1975; **197**: 65–9. OS
- 717) Ferguson RK. Cost and yield of the hypertensive evaluation. Experience of a community-based referral clinic. *Ann Intern Med* 1975; **82**: 761–5. OS
- 718) Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. *Br Med J* 1976; **2**: 554–6. OS
- 719) Danielson M, Dammström B. The prevalence of secondary and curable hypertension. *Acta Med Scand* 1981; **209**: 451–5. OS
- 720) Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. *Arch Intern Med* 1987; **147**: 1289–93. OS
- 721) Kimura G, Brenner BM. The renal basis for salt sensitivity in hypertension. In: *Hypertension: Pathophysiology, Diagnosis and Management*, 2nd Ed. (edited by Laragh JH & Brenner BM), p. 1569–1588, New York, Raven Press, 1995
- 722) Kimura G. Glomerular function reserve and sodium sensitivity. *Clin Exp Nephrol* 2005; **9**: 102–13. RV
- 723) Kimura G. Clinical pathology and treatment of renin–angiotensin system 2. Chronic kidney disease and the renin–angiotensin system. *Intern Med* 2007; **46**: 1295–8. RV
- 724) Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. *JAMA* 2000; **284**: 2622–4. OS
- 725) Usami T, Sato R, Yoshida A, Kimura G. Regional variation in end-stage renal disease. *Curr Opin Nephrol Hypertens* 2002; **11**: 343–6. RV
- 726) Usami T, Nakao N, Fukuda M, *et al*. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. *Kidney Int* 2003; **64**: 1445–9. OS
- 727) Usami T, Kimura G. Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease. *Clin Exp Nephrol* 2006; **10**: 8–12. RV
- 728) Blythe WB. Natural history of hypertension in renal parenchymal disease. *Am J Kidney Dis* 1985; **5**: A50–6. RV
- 729) Konishi Y, Imanishi M, Okamura M, *et al*. Relationship of renal histological damage to glomerular hypertension in patients with immunoglobulin A nephropathy. *J Hypertens* 2000; **18**: 103–9.
- 730) Preston RA, Singer I, Epstein M. Renal Parenchymal Hypertension: current concepts of pathogenesis and management. *Arch Intern Med* 1996; **156**: 602–11. RV
- 731) Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. *J Am Soc Nephrol* 2003; **14**: 3217–32. RV
- 732) Maschio G, Cagnoli L, Claroni F, *et al*. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. *Nephrol Dial Transplant* 1994; **9**: 265–9. RT

- 733) Jacobson SH, Eklöf O, Eriksson CG, Lins LE, Tidgren B, Winberg J. Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. *BMJ* 1989; **299**: 703–6. OS
- 734) Kincaid-Smith P. Glomerular lesions in atrophic pyelonephritis and reflux nephropathy. *Kidney Int Suppl* 1975; **4**: S81–3.
- 735) 常染色体優性多発性嚢胞腎診療ガイドライン (第2版) 厚生労働省特定疾患対策研究事業 進行性腎障害調査研究班 (富野康日己班長, 東原英二多発性嚢胞腎分科会長) In: 多発性嚢胞腎の全て (東原英二監修) 東京; インターメディア, 2006, p. 294–313, GL
- 736) Mizoguchi M, Tamura T, Yamaki A, Higashihara E, Shimizu Y. Genotypes of autosomal dominant polycystic kidney disease in Japanese. *J Hum Genet* 2002; **47**: 51–4.
- 737) Higashihara E, Nutahara K, Kojima M, *et al.* Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. *Nephron* 1998; **80**: 421–7.
- 738) Higashihara E, Aso Y, Shimazaki J, Ito H, Koiso K, Sakai O. Clinical aspects of polycystic kidney disease. *J Urol* 1992; **147**: 329–32.
- 739) Kelleher CL, McFann KK, Johnson AM, Schrier RW. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. *Am J Hypertens* 2004; **17**: 1029–34. OS
- 740) Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. *N Engl J Med* 1990; **323**: 1091–6. OS
- 741) Maschio G, Alberti D, Janin G, *et al.*; The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *N Engl J Med* 1996; **334**: 939–45. RT
- 742) Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 2000; **35**: 427–32. RT
- 743) van Dijk MA, Breuning MH, Duizer R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant* 2003; **18**: 2314–20. RT
- 744) Jafar TH, Stark PC, Schmid CH, *et al.*; ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. *Kidney Int* 2005; **67**: 265–71. MA
- 745) Nutahara K, Higashihara E, Horie S, *et al.* Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. *Nephron Clin Pract* 2005; **99**: c18–23. RT
- 746) Schrier R, McFann K, Johnson A, *et al.* Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. *J Am Soc Nephrol* 2002; **13**: 1733–9. RT
- 747) Klahr S, Breyer JA, Beck GJ, *et al.*; Modification of Diet in Renal Disease Study Group. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. *J Am Soc Nephrol* 1995; **5**: 2037–47. RT
- 748) Safian RD, Textor SC. Renal-artery stenosis. *N Engl J Med* 2001; **344**: 431–42. RV
- 749) Uzu T, Inoue T, Fujii T, *et al.* Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. *Am J Kidney Dis* 1997; **29**: 733–8. OS
- 750) Kuroda S, Nishida N, Uzu T, *et al.* Prevalence of renal artery stenosis in autopsy patients with stroke. *Stroke* 2000; **31**: 61–5. OS
- 751) Yamashita T, Ito F, Iwakiri N, Mitsuyama H, Fujii S, Kitabatake A. Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. *Hypertens Res* 2002; **25**: 553–7. OS
- 752) Nakamura S, Iihara K, Matayoshi T, *et al.* The incidence and risk factors of renal artery stenosis in patients with severe carotid artery stenosis. *Hypertens Res* 2007; **30**: 839–44. OS
- 753) Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. *J Hypertens* 1997; **15**: 1365–77. RV
- 754) Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. *Ann Intern Med* 1995; **122**: 833–8. CT
- 755) Radermacher J, Chavan A, Bleck J, *et al.* Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. *N Engl J Med* 2001; **344**: 410–7. OS
- 756) Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of

- having renovascular hypertension: a meta-analysis. *Ann Intern Med* 2001; **135**: 401–11. MA
- 757) Tegtmeier CJ, Selby JB, Hartwell GD, Ayers C, Tegtmeier V. Results and complications of angioplasty in fibromuscular disease. *Circulation* 1991; **83**: 1155–61.
- 758) Alhadad A, Mattiasson I, Ivancev K, Gottsäter A, Lindblad B. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. *J Hum Hypertens* 2005; **19**: 761–7.
- 759) Bonelli FS, McKusick MA, Textor SC, *et al.* Renal artery angioplasty: technical results and clinical outcome in 320 patients. *Mayo Clin Proc* 1995; **70**: 1041–52.
- 760) Zeller T, Frank U, Müller C, *et al.* Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. *Circulation* 2003; **108**: 2244–9. CT
- 761) van Jaarsveld BC, Krijnen P, Pieterman H, *et al.*; Dutch Renal Artery Stenosis Intervention Cooperative Study Group. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. *N Engl J Med* 2000; **342**: 1007–14. OS
- 762) Balk E, Raman G, Chung M, *et al.* Effectiveness of management strategies for renal artery stenosis: a systematic review. *Ann Intern Med* 2006; **145**: 901–12. RV
- 763) Nordmann AJ, Logan AG. Balloon angioplasty versus medical therapy for hypertensive patients with renal artery obstruction. *Cochrane Database Syst Rev* 2003; CD002944. RV
- 764) Cooper CJ, Murphy TP, Matsumoto A, *et al.* Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. *Am Heart J* 2006; **152**: 59–66. RT
- 765) Mistry S, Ives N, Harding J, *et al.* Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. *J Hum Hypertens* 2007; **21**: 511–5. RT
- 766) Martin LG, Rundback JH, Sacks D, *et al.*; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for angiography, angioplasty, and stent placement in the diagnosis and treatment of renal artery stenosis in adults. *J Vasc Interv Radiol* 2003; **14**: S297–310. GL
- 767) 副島秀久, 池上圭一, 町田二郎, 吉田正貴. 腎血管性高血圧症に対する治療法の変遷と予後. *日泌尿会誌* 1990; **81**: 902–9.
- 768) Williams JS, Williams GH, Raji A, *et al.* Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. *J Hum Hypertens* 2006; **20**: 129–36. OS
- 769) Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. *Biomed Pharmacother* 2000; **54 Suppl 1**: 83s–85s. OS
- 770) Stowasser M, Gordon RD. Primary aldosteronism—careful investigation is essential and rewarding. *Mol Cell Endocrinol* 2004; **217**: 33–9.
- 771) Nishimura M, Uzu T, Fujii T, *et al.* Cardiovascular complications in patients with primary aldosteronism. *Am J Kidney Dis* 1999; **33**: 261–6. OS
- 772) 田辺晶代, 成瀬光栄, 立木美香, 渡辺大輔, 高木佐和子, 高野加寿恵. 原発性アルドステロン症の心血管系合併症: 東京女子医科大学における171例の解析と臨床的示唆. *日本内分泌学会雑誌* 2005; **81**: 20–3.
- 773) Clinical Guidelines of primary aldosteronism. The Endocrine Society. GL
- 774) Gordon RD. Primary aldosteronism. *J Endocrinol Invest* 1995; **18**: 495–511. RV
- 775) Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. *J Clin Endocrinol Metab* 2003; **88**: 2489–94. OS
- 776) Hiramatsu K, Yamada T, Yukimura Y, *et al.* A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. *Arch Intern Med* 1981; **141**: 1589–93.
- 777) Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol (Oxf)* 2007; **66**: 607–18. RV
- 778) Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. *Am J Hypertens* 2002; **15**: 896–902. OS
- 779) Schirpenbach C, Seiler L, Maser-Gluth C, *et al.* Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. *Eur J Endocrinol* 2006; **154**: 865–73. OS
- 780) Morimoto S, Takeda R, Murakami M. Does pro-

- longed pretreatment with large doses of spironolactone hasten a recovery from juxtaglomerular-adrenal suppression in primary aldosteronism? *J Clin Endocrinol Metab* 1970; **31**: 659–64. CT
- 781) 日本内分泌学会ホームページ: http://square.umin.ac.jp/endocrine/rinsho_juyo/index.html
- 782) Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. *Clin Endocrinol (Oxf)* 2004; **61**: 768–77. OS
- 783) 宮地幸隆. 厚生科学研究費補助金特定疾患対策研究事業「副腎ホルモン産生異常に関する研究班」平成13年度研究報告書.
- 784) 名和田新, 高柳諒一. 副腎ホルモン産生異常症の全国疫学調査, 厚生省特定疾患内分泌系疾患調査研究班「副腎ホルモン産生異常症」調査分科会 平成10年度研究報告書. 1999; P47.
- 785) Neumann HP, Cybulla M, Shibata H, *et al.* New genetic causes of pheochromocytoma: current concepts and the clinical relevance. *Keio J Med* 2005; **54**: 15–21. RV
- 786) 日本甲状腺学会. 日本甲状腺学会 [internet]. [参照日 2008年3月19日]. <http://thyroid.umin.ac.jp/flame.html> より「診療ガイドライン」でリンク GL
- 787) 小林靖, 橋本博史. 大動脈炎症候群 (高安動脈炎) 診断・治療指針. 厚生科学研究費補助金: 特定疾患対策研究事業. 難治性血管炎に関する調査研究, 平成11~13年度総合研究報告書. 2002, pp41–63.
- 788) 石川嘉市郎. 高安病高血圧. 領域別症候群シリーズ12循環器症候群 (日本臨床別冊). 1996, p. 118–121.
- 789) 橋本博史. 厚生省特定疾患免疫疾患調査研究班「難治性血管炎分科会」平成13年度研究報告書, 2002, pp21–5.
- 790) Kobayashi Y, Ishii K, Oda K, *et al.* Aortic wall inflammation due to Takayasu arteritis imaged with ¹⁸F-FDG PET coregistered with enhanced CT. *J Nucl Med* 2005; **46**: 917–22.
- 791) 小出桂三. 大動脈炎症候群の疫学調査: 新規発症患者数と合併症について. 厚生省特定疾患難治性血管炎研究班1994年度研究報告書, 1994, pp7–10. OS
- 792) 町田政久, 佐久間まこと, 青木秀俊, 安田慶秀. 高安動脈炎に合併した心大血管病変の長期遠隔成績. 厚生省特定疾患免疫疾患調査研究班1993年度研究報告書 1993. pp192–195. OS
- 793) Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y. Long-term survival after surgical treatment of patients with Takayasu's arteritis. *Circulation* 2003; **108**: 1474–80. OS
- 794) 結節性動脈周囲炎. 厚生省保健医療局疾病対策課監, 難病の診断と治療指針. 愛知; 六法出版社, 1997, p107–115.
- 795) Blaustein DA, Kumbar L, Srivastava M, Avram MM. Polyarteritis nodosa presenting as isolated malignant hypertension. *Am J Hypertens* 2004; **17**: 380–1. OS
- 796) 黒沢美智子, 稲葉 裕, 小林茂人, 尾崎承一, 永井正規. 難治性血管炎 (結節性動脈周囲炎) の平成16年度臨床調査個人票電子化データの分析. 厚生労働科学研究費補助金: 難治性血管炎に関する調査研究班「中・小型血管炎の臨床研究分科会」平成17年度研究報告書, 2006, pp137–150.
- 797) Toro-Salazar OH, Steinberger J, Thomas W, Rocchini AP, Carpenter B, Moller JH. Long-term follow-up of patients after coarctation of the aorta repair. *Am J Cardiol* 2002; **89**: 541–7. OS
- 798) Kobayashi S, Yano M, Kohnno M, *et al.* Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats. *Circulation* 1996; **94**: 3362–8.
- 799) Murakami T, Ueno M, Takeda A, Yakuwa S. Pressure wave reflection after successful balloon dilatation of aortic coarctation. *Circ J* 2007; **71**: 1821–2. OS
- 800) Ross RD, Clapp SK, Gunther S, *et al.* Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. *Am Heart J* 1992; **123**: 1293–9.
- 801) Jannetta PJ, Segal R, Wolfson SK. Neurogenic hypertension: etiology and surgical treatment. I. Observations in 53 patients. *Ann Surg* 1985; **201**: 391–8.
- 802) Morimoto S, Sasaki S, Takeda K, *et al.* Decreases in blood pressure and sympathetic nerve activity by microvascular decompression of the rostral ventrolateral medulla in essential hypertension. *Stroke* 1999; **30**: 1707–10. OS
- 803) Schobel HP, Frank H, Naraghi R, Geiger H, Titz E, Heusser K. Hypertension in patients with neurovascular compression is associated with increased central sympathetic outflow. *J Am Soc Nephrol* 2002; **13**: 35–41.
- 804) Smith PA, Meaney JF, Graham LN, *et al.* Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. *J Am Coll Cardiol* 2004; **43**: 1453–8.
- 805) Nicholas JS, D'Agostino SJ, Patel SJ. Arterial compression of the retro-olivary sulcus of the ventrolateral medulla in essential hypertension and diabetes. *Hypertension* 2005; **46**: 982–5.
- 806) Sendeski MM, Consolim-Colombo FM, Leite CC, Rubira MC, Lessa P, Krieger EM. Increased sympathetic nerve activity correlates with neurovascular compression at the rostral ventrolateral medulla. *Hypertension* 2006; **47**: 988–95.
- 807) Tan EK, Chan LL. Neurovascular compression

- syndromes and hypertension: clinical relevance. *Nat Clin Pract Neurol* 2007; **3**: 416–7. RV
- 808) Brown MJ. The causes of essential hypertension. *Br J Clin Pharmacol* 1996; **42**: 21–7. RV
- 809) Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma DI, de Geus EJ. Heritability of daytime ambulatory blood pressure in an extended twin design. *Hypertension* 2005; **45**: 80–5. OS
- 810) Jeunemaitre X, Soubrier F, Kotelevtsev YV, *et al.* Molecular basis of human hypertension: role of angiotensinogen. *Cell* 1992; **71**: 169–80.
- 811) Kato N, Miyata T, Tabara Y, *et al.* High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. *Hum Mol Genet* 2008; **17**: 617–27.
- 812) Yatsu K, Mizuki N, Hirawa N, *et al.* High-resolution mapping for essential hypertension using microsatellite markers. *Hypertension* 2007; **49**: 446–52.
- 813) Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. *Hypertens Res* 2003; **26**: 521–5. RV
- 814) Hunt SC, Cook NR, Oberman A, *et al.* Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. *Hypertension* 1998; **32**: 393–401. RT
- 815) Arnett DK, Baird AE, Barkley RA, *et al.*; American Heart Association Council on Epidemiology and Prevention. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. *Circulation* 2007; **115**: 2878–901. GL
- 816) Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell* 2001; **104**: 545–56. RV
- 817) 文部科学省. ヒトゲノム・遺伝子解析研究に関する倫理指針. [internet] 参照日 2008年6月13日. http://www.mext.go.jp/a_menu/shinkou/seimei/genome/04122801.htm GL
- 818) Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation* 2007; **115**: 1634–42. GL
- 819) Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in the Netherlands. *Drug Saf* 2008; **31**: 143–58. OS
- 820) Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? *Lancet* 2007; **370**: 2138–51. RV
- 821) Arellano FM, Yood MU, Wentworth CE, *et al.* Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDs) in UK and USA populations. Implications for COX-2 cardiovascular profile. *Pharmacoeconomics Drug Saf* 2006; **15**: 861–72. OS
- 822) Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A; Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. *J Hypertens* 2002; **20**: 1007–14. RT
- 823) Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of glycyrrhetic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate. *Int J Toxicol* 2007; **26 Suppl 2**: 79–112. RV
- 824) 本間真人, 千文, 幸田幸直, 石原三也. 芍薬甘草湯と小柴胡湯の連用が血清カリウム値に及ぼす影響. *薬学雑誌* 2006; **126**: 973–8.
- 825) Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, *et al.* Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2008; **47**: 72–5.
- 826) Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. *Am J Hypertens* 1995; **8**: 823–8.
- 827) Saruta T. Mechanism of glucocorticoid-induced hypertension. *Hypertens Res* 1996; **19**: 1–8. RV
- 828) Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. *J Hum Hypertens* 2000; **14**: 195–8. RT
- 829) Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GJ, Kelly JJ. The nitric oxide system in

- glucocorticoid-induced hypertension. *J Hypertens* 2002; **20**: 1035–43. RV
- 830) Iuchi T, Akaike M, Mitsui T, *et al.* Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. *Circ Res* 2003; **92**: 81–7. CT
- 831) Andoh TF, Johnson RJ, Lam T, Bennett WM. Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. *Am J Transplant* 2001; **1**: 222–7.
- 832) Sander M, Lyson T, Thomas GD, Victor RG. Sympathetic neural mechanisms of cyclosporine-induced hypertension. *Am J Hypertens* 1996; **9**: 121S–138S. RV
- 833) Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. *Am J Hypertens* 2000; **13**: 999–1004.
- 834) Lungu AO, Jin ZG, Yamawaki H, Tanimoto T, Wong C, Berk BC. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. *J Biol Chem* 2004; **279**: 48794–800.
- 835) Halimi JM, Giraudeau B, Buchler M, *et al.* Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. *Clin Transplant* 2007; **21**: 277–84. RT
- 836) 鈴木正司, 合屋忠信. EPO使用基準のガイドライン作成の調査. 平成4年度厚生科学研究腎不全医療研究事業研究報告書, 1993, pp165–172.
- 837) Sasagawa I, Nakada T, Hashimoto T, Kubota Y, Suzuki H, Sawamura T. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. *Int Urol Nephrol* 1994; **26**: 237–43.
- 838) Okura Y, Oshima T, Yasunobu Y, *et al.* Effect of erythropoietin treatment on blood pressure and intracellular cation concentrations in maintenance hemodialysis patients. *Hypertens Res* 1996; **19**: 91–5.
- 839) Shimada N, Saka S, Sekizuka K, *et al.* Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients. *Ren Fail* 2003; **25**: 569–78. OS
- 840) Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. *Am J Med* 1993; **94**: 401–6.
- 841) Miyashita K, Tojo A, Kimura K, *et al.* Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. *Hypertens Res* 2004; **27**: 79–84. CT
- 842) 大久保政明, 石光俊彦, 河口達仁, 阿部実, 八木繁. 腎性貧血を呈する慢性血液透析患者におけるエリスロポエチン長期投与成績. 日本腎臓学会誌1993; **35**: 171–7.
- 843) Iseki K, Nakai S, Shinzato T, *et al.* Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. *Ther Apher Dial* 2007; **11**: 183–8. OS
- 844) Du Y, Melchert HU, Schäfer-Korting M. Use of oral contraceptives in Germany: prevalence, determinants and use-associated health correlates. Results of National Health Surveys from 1984 to 1999. *Eur J Obstet Gynecol Reprod Biol* 2007; **134**: 57–66. OS
- 845) Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. *J Am Geriatr Soc* 1983; **31**: 164–5. OS
- 846) Abo-Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazapine and clonidine. *Pharmacotherapy* 2000; **20**: 476–8. OS
- 847) Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with pheochromocytoma: incidence, prevention and management. *Drug Saf* 2007; **30**: 1031–62. RV